Gefitinib (ZD1839)

Catalog No.S1025

Molecular Weight(MW): 446.90

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Cited by 283 Publications

Cancer Discov, 2019, 9(7):926-943

PubMed: 31092401 ( click the link to review the publication )

Cell Stem Cell, 2019, 25(1):69-86

PubMed: 31080136 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2018, 24(4):512-517

PubMed: 29505033 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):427-438

PubMed: 30205045 ( click the link to review the publication )

Nature, 2017, 547(7664):453-457

PubMed: 28678785 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Nature, 2014, 508(7494):118-22

PubMed: 24670642 ( click the link to review the publication )

Nat Med, 2013, 19(11):1469-1472

PubMed: 24162815 ( click the link to review the publication )

Nature, 2012, 483(7387):100-3

PubMed: 22281684 ( click the link to review the publication )

Cell, 2012, 151(5):937-50

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, 73(1):166-182

PubMed: 30609389 ( click the link to review the publication )

Hepatology, 2019, 10.1002/hep.30780

PubMed: 31127639 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2919

PubMed: 31266962 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )
Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

EMBO J, 2019, 38(4)

PubMed: 30643021 ( click the link to review the publication )

Cancer Res, 2019, 79(4):819-829

PubMed: 30573522 ( click the link to review the publication )

J Am Soc Nephrol, 2019, 30(8):1454-1470

PubMed: 31253651 ( click the link to review the publication )

Matrix Biol, 2019, 10.1016/j.matbio.2019.07.006

PubMed: 31323325 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Int J Cancer, 2019, 145(5):1432-1444

PubMed: 30784054 ( click the link to review the publication )

Oncogene, 2019, 38(11):1936-1950

PubMed: 30390071 ( click the link to review the publication )

Oncogene, 2019, 38(37):6399-6413

PubMed: 31324888 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):46

PubMed: 30709379 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):96

PubMed: 30791926 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31635301 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):77

PubMed: 31262335 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):283

PubMed: 30911072 ( click the link to review the publication )

Signal Transduct Target Ther, 2019, 4:25

PubMed: 31637005 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cell Physiol Biochem, 2019, 53(5):805-819

PubMed: 31670920 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0181

PubMed: 31501278 ( click the link to review the publication )

Cell Prolif, 2019, 52(6):e12680

PubMed: 31454111 ( click the link to review the publication )

Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

Lung Cancer, 2019, 137:85-93

PubMed: 31563735 ( click the link to review the publication )
Cancer Biol Med, 2019, 16(3):606-617

PubMed: 31565489 ( click the link to review the publication )

Artif Cells Nanomed Biotechnol, 2019, 47(1):3231-3238

PubMed: 31373232 ( click the link to review the publication )

DNA Repair (Amst), 2019, 78:37-44

PubMed: 30954901 ( click the link to review the publication )

Front Oncol, 2019, 9:1167

PubMed: 31750252 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31546690 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4488-4497

PubMed: 30679314 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:117

PubMed: 31073278 ( click the link to review the publication )

Mol Carcinog, 2019, 10.1002/mc.23139

PubMed: 31777985 ( click the link to review the publication )

Front Pharmacol, 2019, 10:1116

PubMed: 31649529 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Respir Res, 2019, 20(1):164

PubMed: 31331328 ( click the link to review the publication )

Biomed Pharmacother, 2019, 118:109169

PubMed: 31310954 ( click the link to review the publication )

J Proteomics, 2019, 195:114-124

PubMed: 30660770 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31121829 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

Life Sci, 2019, 224:23-32

PubMed: 30902544 ( click the link to review the publication )

J Drug Target, 2019, 27(4):451-459

PubMed: 30381967 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 106:96-106

PubMed: 30471423 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(11):1516-1524

PubMed: 31450127 ( click the link to review the publication )

Eur J Pharmacol, 2019, 855:10-19

PubMed: 31028739 ( click the link to review the publication )
Eur J Pharmacol, 2019, 850:97-108

PubMed: 30753867 ( click the link to review the publication )

Eur J Pharmacol, 2019, 856:172409

PubMed: 31132355 ( click the link to review the publication )

Biosci Rep, 2019, 39(8)

PubMed: 31316001 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:6033-6043

PubMed: 31440060 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:3129748

PubMed: 31346515 ( click the link to review the publication )

Oncol Lett, 2019, 18(5):5621-5627

PubMed: 31620204 ( click the link to review the publication )

Oncol Lett, 2019, 18(1):368-374

PubMed: 31289508 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3785-3793

PubMed: 31262905 ( click the link to review the publication )

Exp Ther Med, 2019, 17(1):953-959

PubMed: 30651886 ( click the link to review the publication )

Oncotarget, 2019, 10(11):1171-1192

PubMed: 30838090 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

Oncotarget, 2019, 10(26):2546-2560

PubMed: 31069016 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4728

PubMed: 30413706 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(3)

PubMed: 29449326 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3097-3107

PubMed: 29506987 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3928-3940

PubMed: 29685880 ( click the link to review the publication )

Theranostics, 2018, 8(5):1256-1269

PubMed: 29507618 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):109

PubMed: 30157900 ( click the link to review the publication )

Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Cancer Lett, 2018, 424:84-96

PubMed: 29524558 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )
Cancers (Basel), 2018, 10(6)

PubMed: 29925812 ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201800011R

PubMed: 29812969 ( click the link to review the publication )

Exp Mol Med, 2018, 50(1):e435

PubMed: 29371698 ( click the link to review the publication )

Exp Mol Med, 2018, 50(4):52

PubMed: 29700289 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 51(1):337-355

PubMed: 30453282 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):77

PubMed: 30409180 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(10):1892-1908

PubMed: 29970458 ( click the link to review the publication )

Eur J Med Chem, 2018, 144:330-348

PubMed: 29275232 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1458-1469

PubMed: 29934325 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

J Immunol, 2018, 200(8):2809-2818

PubMed: 29531172 ( click the link to review the publication )

Biochem Pharmacol, 2018, 152:327-337

PubMed: 29660315 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(35):13401-13414

PubMed: 29997256 ( click the link to review the publication )

Respir Res, 2018, 19(1):96

PubMed: 29784046 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):50

PubMed: 30053908 ( click the link to review the publication )

Phytomedicine, 2018, 39:33-41

PubMed: 29433681 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2143-2154

PubMed: 29620166 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )
Cancer Biol Ther, 2018, 19(10):921-933

PubMed: 29856687 ( click the link to review the publication )

Cell Cycle, 2018, 17(23):2577-2592

PubMed: 30488756 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2171-2182

PubMed: 30106444 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):1937-1946

PubMed: 30106446 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):775-782

PubMed: 29901173 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8455-8463

PubMed: 30555238 ( click the link to review the publication )

J Ovarian Res, 2018, 11(1):12

PubMed: 29402301 ( click the link to review the publication )

Mol Med Rep, 2018, 18(4):3882-3890

PubMed: 30106133 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):2829-2838

PubMed: 29467862 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(26):18254-18268

PubMed: 29719603 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(42):E9869-E9878

PubMed: 30275324 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Autophagy, 2017, 13(7):1093-1112

PubMed: 28513279 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(15):E3129-E3138

PubMed: 28351972 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1754-1769

PubMed: 28982759 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3551-3563

PubMed: 28428274 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Mol Cancer, 2017, 16(1):34

PubMed: 28158983 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )

Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

J Med Chem, 2017, 60(17):7447-7458

PubMed: 28787156 ( click the link to review the publication )
Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(11):1501-1511

PubMed: 29022575 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Eur J Pharmacol, 2017, 821:21-28

PubMed: 29277715 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1212-1218

PubMed: 27959426 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 493(1):213-219

PubMed: 28899783 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 482(4):1334-1340

PubMed: 27939888 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Oncotarget, 2017, 8(70):115620-115631

PubMed: 29383186 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

J Clin Invest, 2016, 126(9):3296-312

PubMed: 27482886 ( click the link to review the publication )

Nat Commun, 2016, 7:12231

PubMed: 27456471 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

EMBO Rep, 2016, 17(5):724-38

PubMed: 27013495 ( click the link to review the publication )

J Pathol, 2016, 239(3):320-34

PubMed: 27102572 ( click the link to review the publication )

Acta Neuropathol Commun, 2016, 4(1):96

PubMed: 27586084 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )
Oral Oncol, 2016, 59:12-19

PubMed: 27424178 ( click the link to review the publication )

Oral Oncol, 2016, 56:62-70

PubMed: 27086488 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 10.1016/j.bbagen.2016.05.011

PubMed: 27180173 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1859(11):1449-1458

PubMed: 27412911 ( click the link to review the publication )

Clin Lung Cancer, 2016, 17(4):263-270

PubMed: 26707383 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Int J Oncol, 2016, 49(4):1427-36

PubMed: 27498706 ( click the link to review the publication )

Int J Oncol, 2016, 48(3):937-44

PubMed: 26783187 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268 ( click the link to review the publication )

Eur J Pharmacol, 2016, 789:458-467

PubMed: 27514773 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):729-36

PubMed: 27373987 ( click the link to review the publication )

Neurosurg Focus, 2016, 41(6):E14

PubMed: 27903123 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163149

PubMed: 27643613 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(32):52392-52403

PubMed: 27447558 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:6377

PubMed: 25758528 ( click the link to review the publication )

Nat Commun, 2015, 6:6240

PubMed: 25670642 ( click the link to review the publication )

J Thorac Oncol, 2015, 10.1097/JTO.0000000000000500

PubMed: 25658629 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )
Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )

Cancer Lett, 2015, 369(1):103-11

PubMed: 26297988 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10-:2238-48

PubMed: 26208525 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

Lung Cancer, 2015, 88(1):16-23

PubMed: 25704955 ( click the link to review the publication )

J Biol Chem, 2015, 290(41):24784-92

PubMed: 26304118 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )

Int J Oncol, 2015, 46(3):1214-24

PubMed: 25530180 ( click the link to review the publication )

Oncol Rep, 2015, 33(4):1860-6

PubMed: 25634113 ( click the link to review the publication )

Oncol Rep, 2015, 34(3):1613-9

PubMed: 26166014 ( click the link to review the publication )

Oncol Rep, 2015, 34(4):1875-82

PubMed: 26238612 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2795-803

PubMed: 25964559 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2015, 10.1016/j.ijrobp.2015.01.026

PubMed: 25823448 ( click the link to review the publication )

Sci Transl Med, 2014, 6(219):219ra9

PubMed: 24431113 ( click the link to review the publication )

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Int J Cancer, 2014, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Oncogene, 2014, 33(35):4385-95

PubMed: 24096476 ( click the link to review the publication )

MBio, 2014, 5(4):e01340-14

PubMed: 25096879 ( click the link to review the publication )
Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Cell Oncol , 2014, 37(5):377-86

PubMed: 25228008 ( click the link to review the publication )

Lung Cancer, 2014, 85(2):141-6

PubMed: 24957682 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

Colloids and Surfaces B: Biointerfaces, 2014, 123:61-7

PubMed: 25216919 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Int J Oncol, 2014, 45(1):393-400

PubMed: 24819550 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

Am J Physiol Renal Physiol, 2014, 307(4):F435-44

PubMed: 24990892 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 74(3):511-20

PubMed: 25038613 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Horm Cancer, 2014, 289(24):17195-202

PubMed: 24778185 ( click the link to review the publication )

Exp Mol Pathol, 2014, 97(1):154-165

PubMed: 24984270 ( click the link to review the publication )

Langenbecks Arch Surg, 2014, 10.1007/s00423-014-1235-1

PubMed: 25070024 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2014, 88(4):947-54

PubMed: 24606853 ( click the link to review the publication )

University of Alberta, 2014, Yahya Muhammad Fiteih

PubMed: ( click the link to review the publication )
Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

JBUON , 2014, 19(2): 466-473

PubMed: ( click the link to review the publication )

Ann Oncol, 2013, 24(2):362-9

PubMed: 22967992 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):444-53

PubMed: 24258346 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(11):2541-58

PubMed: 24026012 ( click the link to review the publication )

Mol Oncol, 2013, 7(1):121-9

PubMed: 23127547 ( click the link to review the publication )

Carcinogenesis, 2013, 34(9):1994-9

PubMed: 23677069 ( click the link to review the publication )

Cell Prolif, 2013, 46(4):447-56

PubMed: 23829318 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):473-8

PubMed: 23891090 ( click the link to review the publication )

J Biol Chem, 2013, 288(48):34930-42

PubMed: 24142702 ( click the link to review the publication )

Drug Metab Dispos, 2013, 10.1124/dmd.113.054189

PubMed: 24335466 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )

PLoS One, 2013, 8(12):e81393

PubMed: 24339922 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

Exp Mol Pathol, 2013, 94(2):386-97

PubMed: 23399805 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Genet Syndr Gene Ther, 2013, 4

PubMed: 25520884 ( click the link to review the publication )

Herpesviridae, 2013, 4(1):1

PubMed: 23342981 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):1908-16

PubMed: 22722337 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )
Oncogene, 2012, 32(34):4034-42

PubMed: 22964644 ( click the link to review the publication )

Cancer Lett, 2012, 321(2):187-94

PubMed: 22343320 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Biochem Pharmacol, 2012, 84(4):425-31

PubMed: 22634404 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

Int J Oncol, 2012, 41(3):869-75

PubMed: 22752005 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51549

PubMed: 23272116 ( click the link to review the publication )

Oncotarget, 2012, 2(12):1134-44

PubMed: 22193779 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:486

PubMed: 21525872 ( click the link to review the publication )

Oncogene, 2011, 30(6):737-50

PubMed: 20890302 ( click the link to review the publication )

Antivir Res, 2011, 89(1):64-70

PubMed: 21094187 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

Mol Biosyst, 2011, 7(12):3223-33

PubMed: 21956701 ( click the link to review the publication )

Exp Mol Pathol, 2011, 91(1):400-10

PubMed: 21565184 ( click the link to review the publication )

Vet Comp Oncol, 2011, 11(2):124-39

PubMed: 22235915 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Features

A potent EGFR tyrosine kinase inhibitor.

Targets

Tyr1173 (NR6W cells) ^[1]	Tyr1173 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6W cells) ^[1]
26 nM	37 nM	37 nM	57 nM

In vitro

Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nM, in NR6W cells. The NR6wtEGFR and NR6M cell lines has low levels of PLC-γ phosphorylation but the level in the NR6M cell line is more resistant to inhibition by Gefitinib with IC50 of 43 nM and 369 nM, respectively. Gefitinib inhibits Akt phosphorylations, with IC50 of 220 and 263nM, in the low-EGFR- and -EGFRvIII-expressing cell lines, respectively. Gefitinib in the dose range from 0.1 to 0.5μM significantly facilitates, rather than abrogates, colony formation of NR6M cells. However, at a concentration of 2 μM Gefitinib completely blocks NR6M colony formation. Gefitinib rapidly and in a dose-dependent manner inhibits EGFR and ERK phosphorylation up to 72 hours after EGF stimulation in both the high- and low-EGFR-expressing cell lines. ^[1] Gefitinib is the monolayer growth of these EGF-driven untransformed MCF10A cells with an IC50 of 20 nM. ^[2] The combination of Gefitinib (0.2 μM and 0.5 μM) with irradiation lead to a significant growth inhibition in LoVo cells, compared with radiation alone.. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KB	MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnlU45PUUN3ME2wMlA2PCEQvF2=	M4LCUlE3PTF4NEez
NIH3T3	NH3EUpFHfW6ldHnvckBCe3OjeR?=	MW[wMlIh\|ryP	NF\WTGwzKGh?	M1r5SGROW09?	MVrJcohq[mm2aX;uJI9nKEWJRjDzeIlufWyjdHXkJIh2dWGwIHXyZmIyKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODF2NDFOwG0>	MVOxOlQ5ODJ6NB?=
COS7	M4PFW2Z2dmO2aX;uJGF{e2G7	MV[5OkDPxE1?			MVjJcohq[mm2aX;uJI9nKGi3bXHuJGpCUzJiVk[xO2YhdXW2YX70JIV5eHKnc4Pl[C=>	NV7kdmx7OTdzN{i3NlI>
A549	MUfDfZRwfG:6aXOgRZN{[Xl?		MV[5OkBp	MoXYSG1UVw>?	NYPBUXM6UUN3ME2xN{42QSEQvF2=	MVGxPFMyOzhyNx?=
K562	NYLMWmZSS3m2b4TvfIlkKEG\|c3H5		M1PCPFk3KGh?	NWnsRpNrTE2VTx?=	MlvyTWM2OD17LkO2JO69VQ>?	MnnSNVg{OTN6MEe=
MDA-MB-231	NFi5V2lEgXSxdH;4bYMhSXO\|YYm=		NHm1XZU6PiCq	MkP2SG1UVw>?	MlnlTWM2OD1\|Nj62NUDPxE1?	NGHaU2syQDNzM{iwOy=>
MOLT4	MmXER5l1d3SxeHnjJGF{e2G7		NUnjVpB1QTZiaB?=	NUj1Om5XTE2VTx?=	MXHJR\|UxRTF3LkCyJO69VQ>?	NF7IUlIyQDNzM{iwOy=>
MCF7	M2Lx[2N6fG:2b4jpZ{BCe3OjeR?=	NIPGbGY2OCEQvF2=	Mln0O\|IhcA>?		MkjDTWM2OD1zMj6wOUDPxE1?	NYHyNGt6OTh5N{G4NVk>
BT474	NYjHe2dMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVq3NkBp		NU[1T2xGSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDCWFQ4PCClZXzsd{BwfmW{ZYjwdoV{e2mwZzDFVmJjOiC5aYToJGVEPTBib3[gNE4{KM7:TR?=	MWWxPVAzQDR{NB?=
HN5	NF62R4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXO0fVV7PzJiaB?=		NWTITXVGSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUlUh[2WubIOgc5ZmemW6cILld5NqdmdiRVfGVkB4cXSqIFXDOVAhd2ZiMD6wNUDPxE1?	Mn\GNVkxOjh2MkS=
BA/F3	M37hfmN6fG:2b4jpZ{BCe3OjeR?=		MV[3NkBp		M{L0TWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiRVfGVkBNQDV6UjDteZRidnRid3n0bEBKSzVyIH;mJFAvODFyODFOwG0>	NHnCNGYyQTJ\|OUKyPS=>
NIH3T3	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUe3NkBp		MWfHdo94fGhiaX7obYJqfGmxbjDv[kBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGW6cILld5NqdmdiZYLCNkBo\W6nIIfpeIghUUN3MDDv[kAxNjV2IN88US=>	NUTmeWpLOTl4NkWzO\|c>
MCF7 MX	M4HOTWZ2dmO2aX;uJGF{e2G7		MnHPN\|AhdWmw		MU\Jcohq[mm2aX;uJI9nKEKFUmCg[ZhxemW\|c3XkJJdqfGhiSVO1NEBw\iBzLkGg{txO	NVfQV3Q5OTl7M{K5OlA>
A431	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUCxNEDPxE1?	NXXkNJlDPzJiaB?=		M3W2SGdKPTB;MD61NVQh\|ryP	M2nFWVE6QTZ7NE[1
A431	NUTKUpJbU2mwYYPlJGF{e2G7	M2X3RlAvOSEQvF2=	NX:1W41WOSCq		NGPOcW5KdmirYnn0bY9vKG:oIFXHSk1qdmS3Y3XkJGVITlJicHjvd5Bpd3K7bHH0bY9v	NGrGVXgyQTl4OUS2OS=>
A431	MmLnT4lv[XOnIFHzd4F6	MnvONVAxKM7:TR?=	NXTjfm4zOTBibXnu		M{PWfXBzd2yxbnfl[EBqdmirYnn0c5J6KGGldHn2bZR6KG:oIFXHSk1qdmS3Y3XkJGVITlJicHjvd5Bpd3K7bHH0bY9v	NEjxV2UyQTl4OUS2OS=>
Sf9	M1jPXGtqdmG\|ZTDBd5NigQ>?		MlzqNVAhdWmw	NGHGVY9FVVOR	NYewbZFPUW6qaXLpeIlwdiCxZjDFS2ZTKGW6cILld5Nm\CCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKnY3XweI9zKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODN\|IN88US=>	MnnJNlAxPTZ2MkW=
NCI-H1975	NITwboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV61JO69VQ>?	MmHHO\|IhcA>?		MoizTWM2OD16LkK2JO69VQ>?	NIX0fI0zODF3MU[3NC=>
NCI-H1975	MnO3T4lv[XOnIFHzd4F6	M1qyfVExKM7:TR?=			NWDwXZFoUW6qaXLpeIlwdiCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25?	NVfVW5RJOjBzNUG2O\|A>
NCI-H1975	NF\3VpBHfW6ldHnvckBCe3OjeR?=	MoHKNVAh\|ryP			M3PHd2lvcGmkaYTpc44hd2ZiRWLCRlIh[XW2b4Doc5NxcG:{eXzheIlwdg>?	M1PRXVIxOTVzNkew
NCI-H1975	MlPXSpVv[3Srb36gRZN{[Xl?	NF;IWGk2KM7:TR?=	MYW0PEBp		MnjnTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCjc4Pld5Nm\CCjczDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4UuOw>?	Ml;CNlAyPTF4N{C=
A375	Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXW0PEBp		NWXWPVk5UUN3ME2yNE42PSEQvF2=	M4PnTVIxOzB2NUO3
SMMC7721	NWTJOHg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M33JflQ5KGh?		M1r2RmlEPTB;M{OuNVIh\|ryP	NFLhelEzODNyNEWzOy=>
DU145	M{nvWmN6fG:2b4jpZ{BCe3OjeR?=		MVy1JIQ>	M2LxR2ROW09?	NVH3dlRiUUN3ME20Nk4yPyEQvF2=	M{jVO\|IxPDZ4NUW1
MIAPaCa2	MYjDfZRwfG:6aXOgRZN{[Xl?		MoPVOUBl	MWTEUXNQ	MUDJR\|UxRTVyLk[yJO69VQ>?	M4PBeVIxPDZ4NUW1
PANC1	M3nOXGN6fG:2b4jpZ{BCe3OjeR?=		MnO5OUBl	NELFcINFVVOR	NWj2ZotRUUN3ME20NE41OiEQvF2=	NHvRXZMzODR4NkW1OS=>
PC9	NHLMfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\NXY1FSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBGT0[ULXTl[olkcWWwdDDoeY1idiCSQ{mgZ4VtdHNid3n0bEBGSzVyIH;mJFAvODF5IN88US=>	NUTnT4c1OjF{MEi4NFI>
PC9	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrXTY53SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBoem:5dHitdoV{cXO2YX70JIh2dWGwIGDDPUBk\WyuczDlfJBz\XO\|aX7nJGVITlJiRUe0On9CPzVyL2S3PVBOKG23dHHueEB4cXSqIFXDOVAhd2ZiNzFOwG0>	MX[yNVIxQDhyMh?=
PC3	MkjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzpNIgyOCEQvF2=	MW[3NkBp	MYfEUXNQ	M3y0WmlEPTB;Nz60JO69VQ>?	NELkVlUzOTN3M{W0Oi=>
MDA-MB-468	NUHVTI9oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVexNFAh\|ryP	NFHvdms1QCCq	NY[4XZRLTE2VTx?=	NXLBSpVZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJk>	NGLkUmYzOTR{OU[zNi=>
Plasmodium falciparum					M4XsR5FJXFNicILv[oltcW6pIH\vdkBqdmirYnn0c5J{KG:oIGDsZZNud2SrdX2g[oFt[2myYYL1cUBxem:uaX\ldoF1cW:w	Mn3FNlE5OTdyNEW=
NCI-H1993	MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkWwO\|IhcA>?	NEL1dGhFVVOR	MmPiTWM2OD1yLkGg{txO	MnTTNlE6OTZ2M{O=
NCI-H292	NX\IbpV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn3JO\|IhcA>?	MV7EUXNQ	M2\ZfGlEPTB;MD6wNkDPxE1?	MYWyNVkyPjR\|Mx?=
A431	MUjLbY5ie2ViQYPzZZk>		NYTUOoZzOiCq	NVHBbpBCTE2VTx?=	NFzRTZBKdmirYnn0bY9vKG:oIFXHSnIheGixc4Doc5J6dGG2aX;uJIlvKEWJRj3zeIlufWyjdHXkJIh2dWGwIFG0N\|Ehf2m2aDDJR\|UxKG:oIECuNFAyKM7:TR?=	MVGyNlExOTF\|Mh?=
MCF7	NWLyfW9tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnRRWY4OTBywrFOwIcwdUx?	Mn2zOFghcA>?	NGrRfIVFVVOR	NWrrb\|J1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJI93\XKneIDy[ZN{cW6pIFXHSnIh\2WwZTD3bZRpKEmFNUCgc4YhOTJwMEWg{txO	MWCyNlEyQTF\|MB?=
BT474	MkjJR5l1d3SxeHnjJGF{e2G7	NFXpTpcyOCEQvF2=	NUTJPItzPDhiaB?=		MWnDfZRwfG:6aXPpeJkh[WejaX7zeEB{\XK3bT3zeIFzfmWmIHj1cYFvKEKWNEe0JINmdGy\|	NILuUYkzOjF\|OEOwPC=>
MCF7	NVfHZml2S3m2b4TvfIlkKEG\|c3H5	NEPSc\|IyOCEQvF2=	NVPQOVR1PDhiaB?=		MmTPR5l1d3SxeHnjbZR6KGGpYXnud5Qhe2W{dX2td5Rien[nZDDoeY1idiCPQ1[3JINmdGy\|IH;2[ZIu\XiycnXzd4lv\yCHcnLCNkBk\Wyucx?=	NX7Ee3F{OjJzM{izNFg>
HCC827	NYPaSXVmU2mwYYPlJGF{e2G7	NFqwcWQxNjF{NTFOwG0>	MnfjNlQhcA>?	MYTEUXNQ	NVn6TppiUW6qaXLpeIlwdiCxZjDFS2ZTKGSnbDDFO\|Q3NUF5NUCgcZV1[W62IGmxNFY5KGG3dH;wbI9{eGixconsZZRqd25?	NULTZZhyOjJ\|M{mzOFI>
HCC827	MWjLbY5ie2ViQYPzZZk>	Ml[yNE4yOjVizszN	MViyOEBp	MnLUSG1UVw>?	MlLGTY5pcWKrdHnvckBw\iCHR1\SJIRmdCCHN{S2MWE4PTBibYX0ZY51NW2nZHnheIVlKEW{azDwbI9{eGixconsZZRqd25?	NHX3e3EzOjN\|OUO0Ni=>
HCC827	MXfLbY5ie2ViQYPzZZk>	MWWwMlEzPSEQvF2=	M1\hXlI1KGh?	NUHTdXdFTE2VTx?=	NHzocYxKdmirYnn0bY9vKG:oIFXHSnIh\GWuIFW3OFYuSTd3MDDteZRidnRvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?=	NIPN[5MzOjN\|OUO0Ni=>
A431	M2XIbGtqdmG\|ZTDBd5NigQ>?	MUWxNFAh\|ryP	MkewN\|AhdWmw		NEDR[ZBKdmirYnn0bY9vKG:oIFXHSnIh\GW{aY\l[EBnem:vIHj1cYFvKEF2M{GgZ4VtdCCvZX3idoFv\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHCxbImtS4x2NVS7cjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFEvODhizszN	MVWyNlY6QDd6Mh?=
H460	M4nQe2N6fG:2b4jpZ{BCe3OjeR?=		MUK3NkBp		M1jZV2lEPTB;NT61PUDPxE1?	M1PHV\|IzPzJ5NES5
HT-29	M1u0VWN6fG:2b4jpZ{BCe3OjeR?=		NXezWohzPzJiaB?=		NXG0SIpWUUN3ME2zMlM3KM7:TR?=	NGrxd3YzOjd{N{S0PS=>
SGC7901	MV3DfZRwfG:6aXOgRZN{[Xl?		NFvtZ2k4OiCq		MXfJR\|UxRTFyLkK2JO69VQ>?	M3m3flIzPzJ5NES5
A498	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLlXYxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG0PVgh[2WubIOg[ZhxemW\|c3nu[{BGT0[UIHHu[EBUWkNid3n0bEBKSzVyIH;mJFgvPiEQvF2=	MnexNlI5OTh6NEi=
Calu3	NEHkOXZEgXSxdH;4bYMhSXO\|YYm=	NEO3Z\|EyOCEQvHevcWw>	M4DIbVczKGh?		MXnJR\|UxRTFwNjFOwG0>	MUGyN\|EyPjF4OB?=
FADU	M3nHbmN6fG:2b4jpZ{BCe3OjeR?=	M1HyVlExKM7:Zz;tUC=>	Moq2O\|IhcA>?		M2TsWGlEPTB;MD6wOUDPxE1?	NInIUXgzOzFzNkG2PC=>
HCC827	M4PnbmN6fG:2b4jpZ{BCe3OjeR?=	M3yweVExKM7:Zz;tUC=>	Mn\QO\|IhcA>?		MVPJR\|UxRTBwMECxOUDPxE1?	MlfUNlMyOTZzNki=
PC9	M{\PcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXXNVAh\|rypL33M	MWO3NkBp		NWn2NnF3UUN3ME2wMlAyPCEQvF2=	NWTYUmJyOjNzMU[xOlg>
Sf9	NGDPdoNMcW6jc3WgRZN{[Xl?		NVLjdY17OSCq	MmPpSG1UVw>?	MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGdUXC22YXfn[YQhTUeIUjDMPFM1WiCvdYThcpQh\XiycnXzd4VlKHerdHigTWM2OCCxZjCwMlAyPSEQvF2=	NHq2VWEzOzZzMU[5NS=>
16HBE14o-	NXG5To9vS3m2b4TvfIlkKEG\|c3H5	MXSxNEDPxE1?	M4qxN\|czKGh?	MkPVSG1UVw>?	M4LhVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJFE3UEKHMUTvMUBk\WyuczDoZZJjd3Krbnege4lt\CC2eYDlJGVITlJiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDF{LkexJO69VQ>?	Mk[yNlM3Pjh2NEG=
NCI-H1975	NYDiNHpsS3m2b4TvfIlkKEG\|c3H5	MUCxNEDPxE1?	M{PqZ\|czKGh?	NUDUbo9oTE2VTx?=	Mor6R5l1d3SxeHnjbZR6KGGpYXnud5Qh\2WoaYTpcoljNXKnc3nzeIFvfCCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgbIFz[m:{aX7nJGVITlJiTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfCCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhPi57MUeg{txO	M4nDR\|I{PjZ6NESx
16HBE	NXzCcodUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXm3NkBp	MX\EUXNQ	NETSTWVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIEG2TGJGKGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEWJRmKge4l1cCCLQ{WwJI9nKDFwNkCxJO69VQ>?	M{nw[\|I{Pzl{M{G4
16HBE	MkPOSpVv[3Srb36gRZN{[Xl?	M2LNTlExOCEQvF2=	NInheGkyPTBibXnu	NHf6bXZFVVOR	MlXzTY5lfWO2aX;uJI9nKG6rdILpZ{BwgGmmZTDwdo9lfWO2aX;uJIlvKGi3bXHuJFE3UEKHIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXHSnI>	MWGyN\|c6OjNzOB?=
A549	MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVe3NkBp	NF3GZYFFVVOR	MlrHRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDD3bYxlKHS7cHWgSWdHWi:tLWLhd{Bl\XCnbnTlcpQhcHWvYX6gRVU1QSClZXzsd{B4cXSqIFnDOVAhd2ZiND62NlYh\|ryP	MXyyN\|c6OjNzOB?=
SH-SY5Y	MXLDfZRwfG:6aXOgRZN{[Xl?		NFfDUoQ4OiCq		Mn[4TWM2OD1zOD6yNUDPxE1?	NXv1PYJYOjN6N{G5NFk>
LoVo	NELTUXZMcW6jc3WgRZN{[Xl?		MmXwNkAhcA>?	NGnZOnNFVVOR	MkX2TY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yNkKg{txO	NHz1cWszOzl\|MEm5OC=>
PC9	MlP1T4lv[XOnIFHzd4F6		MV6yJIg>	MV3EUXNQ	MVvJcohq[mm2aX;uJI9nKEWJRmKg[ZhwdiBzOTDk[YxmfGmxbjDhZ5RqfmG2aX7nJI12fGGwdDDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iUFO5JINmdGy\|IIfpeIghUUN3MDDv[kAxNjByOEeg{txO	NYXnW2x5OjN7M{C5PVQ>
HCC827	MmG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NX;De405PzJiaB?=		NWXQdFVEUUN3ME2wMlAyOiEQvF2=	MXyyN\|k4OzF4OB?=
A549	MXXLbY5ie2ViQYPzZZk>	MUCxJO69VQ>?	NX:2emxpOSCq	MoWwSG1UVw>?	MYfJcohq[mm2aX;uJI9nKEWJRmKgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wN\|k6KM7:TR?=	Mny3NlM6QDh\|NUS=
A549	MWrGeY5kfGmxbjDBd5NigQ>?	Mn:4NUDPxE1?	MlHuNUBp	M1\oTGROW09?	MnfVR4VtdHWuYYKgeZB1[Wun	MnToNlM6QDh\|NUS=
HCC827	NYX2T5NlU2mwYYPlJGF{e2G7	NYXGc2VFOC53IN88US=>	MljGNkBp	MnnoSG1UVw>?	NULjNWl3UW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCpZX\peIlvcWJvcnXzbZN1[W62IHj1cYFvKEiFQ{iyO{Bk\Wyucx?=	MU[yN\|k6OzN{OB?=
HCC827	NW\wb5dOTnWwY4Tpc44hSXO\|YYm=	MW[wMlUh\|ryP	NYDSNoZpOiCq	NIjTb2hFVVOR	M133RWlvcGmkaYTpc44hd2ZiYz3N[ZQheGixc4Doc5J6dGG2aX;uJIlvKGenZnn0bY5q[i2{ZYPpd5RidnRiaIXtZY4hUEOFOEK3JINmdGy\|	MXyyN\|k6OzN{OB?=
HCC827	NX[2OWl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mly3NVAh\|ryP	MXS3NkBp	MoDaSG1UVw>?	NV;vfI9YSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBo\W[rdHnubYIue2Wwc3n0bZZmKGi3bXHuJGhESzh{NzDj[YxteyCqYYLic5JqdmdiRVfGVkBGPzR4IITvJGE4PTBiZHXs[ZRqd25id3n0bEBKSzVyIH;mJFAvODB3OEGg{txO	NUjJTZg6OjRyNUO2O\|Q>
A431	MUnLbY5ie2ViQYPzZZk>	Mlz5NVAxKM7:TR?=	MmLpN\|AhdWmw		NHzOVIdKdmirYnn0bY9vKG:oIFXHSnIhcW5ic3jl[EBu\W2kcnHu[UB3\XOrY3zld{B4cXSqIFnDOVAhd2ZiMT6xJO69VQ>?	MmXCNlQxQTR2M{K=
BCRP-MDCK2	M1HPZ2Z2dmO2aX;uJGF{e2G7	M1ztPVEvQCEQvF2=	MmLSO\|IhcA>?	MlHTSG1UVw>?	NHi4XZdKdmO{ZXHz[UBw\iCybHHzcYEhdWWvYoLhcoUh\XiycnXzd4lwdiCxZjDCR3JRKGW6cILld5NqdmdicnXwc5J1\XJiZ3Xu[UBITlB?	MnnZNlQyQDR{MUO=
BCRP-MDCK2	MnH3SpVv[3Srb36gRZN{[Xl?	NF;1W2syNjhizszN	MU[3NkBp	NHvXUoFFVVOR	M3SxbHJm\HWldHnvckBw\iCybHHzcYEhdWWvYoLhcoUh\XiycnXzd4lwdiCxZjDCR3JRKGW6cILld5NqdmdicnXwc5J1\XJiZ3Xu[UBITlB?	NXHHbXFtOjRzOESyNVM>
MDCK	NX;mcItuS3m2b4TvfIlkKEG\|c3H5		MUK3NkBp	Ml7CSG1UVw>?	MULHTVUxRTFwNEWg{txO	NX72[mJtOjRzOESyNVM>
MDCK2	MmTSSpVv[3Srb36gRZN{[Xl?	M2DGbFEvQCEQvF2=	MnjGO\|IhcA>?	M3zJdGROW09?	M1T6b2lvcGmkaYTpc44hd2ZiaIXtZY4hSkOUUDDlfJBz\XO\|ZXSgZZN{\XO\|ZXSgZZMhUG:nY3jzeEA{OzN2MjDhZ4N2dXWuYYTpc44hf2m2aDDJR\|UxKG:oIEOuNVkh\|ryP	MVeyOFE5PDJzMx?=
A431	NVTCcJFpS3m2b4TvfIlkKEG\|c3H5		M1LYPVczKGh?	NYDDRm5QTE2VTx?=	MknqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{BmgHC{ZYPzbY5oKEWJRmKge4l1cCCLQ{WwJI9nKDBwNUWg{txO	NFzvdG4zPDRzMUGyNy=>
Calu3	MXPDfZRwfG:6aXOgRZN{[Xl?		MX63NkBp	NGLkUJJFVVOR	MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDZYx2OyClZXzsd{BmgHC{ZYPzbY5oKEiHUkKge4l1cCCLQ{WwJI9nKDBwOUmg{txO	MV6yOFQyOTF{Mx?=
KB	NEG2[XRMcW6jc3WgRZN{[Xl?	M4HC[VExKM7:TR?=	NF[1NVkyKGh?	NUDndFROTE2VTx?=	MVrJcohq[mm2aX;uJI9nKEWJRj3zeIlufWyjdHXkJIF2fG:yaH;zdIhwenmuYYTpc44hd2ZiRVfGVkB4cXSqIFnDOVAhd2ZiMD6wNlUh\|ryP	NVfncWo4OjR2MUGxNlM>
BEAS2B	NXPwNWhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmP5OVAh\|ryP	NXXoPYFsPzJiaB?=	M2DRdmROW09?	NVuxdlR{UUN3ME2xN{46PCEQvF2=	NXjuWXIyOjR4MEe1PVE>
NCI-H1975	MYDGeY5kfGmxbjDBd5NigQ>?	MnLSNVAxKM7:TR?=	MnTXNVUxKG2rbh?=	NVnKR5ZjTE2VTx?=	NEC4OWxKdmS3Y4Tpc44hd2ZiTl:gdJJw\HWldHnvckBqdiCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgbIFz[m:{aX7nJGVITlJiTEi1PHIwXDd7MF2gcZV1[W62	NXmydYRoOjR4MEe1PVE>
Hela	M{jOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Moi4NlQhcA>?	MkDoSG1UVw>?	NGTvSWRKSzVyPUKuOlch\|ryP	NFjOT\|gzPDd\|MUK4NS=>
HepG2	M4L4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWOyOEBp	NWDpVJFFTE2VTx?=	NGi5cXhKSzVyPU[uOFIh\|ryP	MnHxNlQ4OzF{OEG=
Sf9	MXrLbY5ie2ViQYPzZZk>		MmrrNVAhdWmw	NECwNWxFVVOR	NF3VV2lKdmirYnn0bY9vKG:oIHH1eI9xcG:\|cHjvdplt[XSrb36gc4YhemWlb33ibY5idnRiaHnzMZRi\2enZDDFS2ZTKCijbXnuc{Bi[2mmIE[0OU0yOTh4KTDlfJBz\XO\|ZXSge4l1cCCLQ{WwJI9nKDBwMEKg{txO	MofwNlQ4OzF{OEG=
SW620	NV3zeoR2S3m2b4TvfIlkKEG\|c3H5		MV[0PEBp	MlLqSG1UVw>?	M3;1cWlEPTB;MkiuNkDPxE1?	NY\0eIhkOjR7MEC1PVQ>
HCC827	NYf3SWZGTnWwY4Tpc44hSXO\|YYm=	MYiwMlUh\|ryP	MlWyNkBp	M3X3SWROW09?	MXfkc4V{KG6xdDDpcohq[mm2IHOtUYV1KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhSUuWIIDoc5NxcG:{eXzheIlwdg>?	NWPCbGtrOjN7OUOzNlg>
HCC827	MXXGeY5kfGmxbjDBd5NigQ>?	MVewMlUh\|ryP	M{fKVFIhcA>?	MWXEUXNQ	M4PuWYRw\XNibn;0JIlvcGmkaYSgZ{1O\XRiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyNESvOFIheGixc4Doc5J6dGG2aX;u	M1[3dlI{QTl\|M{K4
HCC827	NXXIOlM1S3m2b4TvfIlkKEG\|c3H5	M2DsTlAvPSEQvF2=	NXHXXIZoPzJiaB?=	MnPaSG1UVw>?	M1vHPIhieyCwbzDjfZRwfG:6aXPpeJk>	MUKyN\|k6OzN{OB?=
NCI-H1975	NIm4NFhHfW6ldHnvckBCe3OjeR?=	M{XWVFExKM7:TR?=	M2i5OlghcA>?	MVPEUXNQ	M4LaU4Rw\XNibn;0JIlvcGmkaYTpJGVITlJiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEWUSzDwbI9{eGixconsZZRqd25?	M2TxS\|I{OTF4MU[4
A431	M3rzeWtqdmG\|ZTDBd5NigQ>?	NY\k[Jg2OSEQvF2=	NWTxVJZDOSCq	NWH2cIJjTE2VTx?=	MluxbIF{KG6xIHnydoV3\XK\|aXLs[UBqdmirYnn0bY9vKG:oIFXHSnIh[XW2b4Doc5NxcG:{eXzheIlwdg>?	MY[yOFkxODV7NB?=
LNCaP	M1LOXGZ2dmO2aX;uJGF{e2G7	NGS4TIgyOCEQvF2=	MnnnNoghd3JiNDDo	M1n0OWROW09?	M1jvToRw\XNibn;0JIlvcGmkaYSgZZV1d3Cqb4PwbI9zgWyjdHnvckBw\iCrbX31co9xfXKrZnnl[EBndGGpLYTh[4dm\CCEbYigZZN{\XO\|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcOzKSXVHUVC=>	NHnZenoyQDZ4N{OxNi=>
H1975	MVPLbY5ie2ViQYPzZZk>	NYDFcYZCOSEQvF2=	MkXpNlQhcA>?	NX[xZZFnTE2VTx?=	NILNc\|Vld2W\|IH7veEBqdmirYnn0JGVITlJicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q4QTCPIH31eIFvfA>?	M2PGc\|I1PjB5NUmx
H1975	NITmbm1HfW6ldHnvckBCe3OjeR?=	NUnxcGdWOSEQvF2=	NYfYRoFQOjRiaB?=	MUDEUXNQ	Mm\j[I9meyCwb4SgbY5pcWKrdDDFVmsheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGgyQTd3IHPlcIx{KGijcnLvdolv\yCHR1\SJGw5PTiUL2S3PVBO	M2\LZ\|I1PjB5NUmx
HCC827	M4n3[2tqdmG\|ZTDBd5NigQ>?	M3foPVAvOTFizszN	M3;HZlEhcA>?	M1rDd2ROW09?	NHXESXpp[XNibn:gbZJz\X[ncoPpZoxmKGmwaHnibZRqd25ib3[gSWdHWiCjc4Pld5Nm\CCjczDy[YNwfmW{eTDv[kBGT0[UIHH1eI9xcG:\|cHjvdplt[XSrb36=	M4f5[\|I1OTJ2OEm4
H1975	NXrE[o03U2mwYYPlJGF{e2G7	MVGwMlM{KM7:TR?=	M3LxPFIhcA>?	M1XWbGROW09?	MonF[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGFMXCCyaH;zdIhwenmuYYTpc44>	MWKyOFEzPDh7OB?=
H1975	M2rlWGtqdmG\|ZTDBd5NigQ>?	MWCwMlM{KM7:TR?=	Mn7rNkBp	NFrwSFVFVVOR	MUnkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1iZH;1ZoxmKG23dHHueEBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gSXJMKHCqb4PwbI9zgWyjdHnvci=>	M4\tZVI1OTJ2OEm4
H1975	M{\s[GtqdmG\|ZTDBd5NigQ>?	Mn:wNE4{OyEQvF2=	Ml7NNkBp	MmfnSG1UVw>?	NGfETYNld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfCCyaH;zdIhwenmuYYTpc44>	NFmx[oIzPDF{NEi5PC=>
H1975	NWjBUW9zU2mwYYPlJGF{e2G7	MmDhNE4yOjVizszN	MVyyOEBp	NUnTZWxOTE2VTx?=	MnvY[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIH31eIFvfCC\MUC2PEBifXSxcHjvd5Bpd3K7bHH0bY9v	NGjPV\|QzOjN\|OUO0Ni=>
H1975	MX\LbY5ie2ViQYPzZZk>	NF;teGoxNjVizszN	NX:1NYFHOjRiaB?=	MkfMSG1UVw>?	MoHT[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIH31eIFvfC2vZXTpZZRm\CCHcnugdIhwe3Cqb4L5cIF1cW:w	M3jTWVIzOzN7M{Sy
H1975	NFfVdGRMcW6jc3WgRZN{[Xl?	MXywMlUh\|ryP	NUXpWnhpOjRiaB?=	MWrEUXNQ	MXHkc4V{KG6xdDDpcohq[mm2IFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51NW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25?	NXPCO29qOjJ\|M{mzOFI>
MIAPaCa2	MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\xbFIvPSEQvF2=	MV:3NkBp	M3T3b2ROW09?	Mni4bIF{KG6xIHfyc5d1cCCrbnjpZol1cW:w	M4q5bVIxPDZ4NUW1
MIAPaCa2	MnK2R5l1d3SxeHnjJGF{e2G7	NYjQfZVpOSEQvF2=	M1;zR\|ExKGR?	NF7T[YZFVVOR	MVvoZZMhdm9iY4n0c5RwgGmlaYT5JIF{e2W\|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJINwdG:weTDmc5Ju[XSrb36=	Mmn4NlA1PjZ3NUW=
MIAPaCa2	NELrTYtCeG:ydH;zbZMhSXO\|YYm=	MWGxNEDPxE1?	NGfnUXQzPGhib4KgOFghcA>?	NYrnS4FMTE2VTx?=	NE\ye2pld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nz	NGSyfYszODR4NkW1OS=>
MIAPaCa2	M{PCW2Fxd3C2b4Ppd{BCe3OjeR?=	MYCyNEDPxE1?	NULDNIdEOjRiaB?=	MmLPSG1UVw>?	MnvD[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{Bk[XOyYYPlJFMh[WO2aY\heIlwdg>?	M4D3U\|IxPDZ4NUW1
EoL-1	MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITUcFZKSzVyPUWuNVchdk1?	MnfUV2FPT0WU
NCI-H720	MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XCOmlEPTB;Mk[uPVIhdk1?	M3nnfHNCVkeHUh?=
NCI-SNU-5	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonQTWM2OD1{OD6xPUBvVQ>?	M{iyenNCVkeHUh?=
EW-3	NWS5bGVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGe0U4pKSzVyPUS2MlA1KG6P	NW\BU5JkW0GQR1XS
HCC2218	M{nX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjM[49KSzVyPUWwMlU6KG6P	MYHTRW5ITVJ?
HuO-3N1	M2[4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmP5TWM2OD13Nj6wPUBvVQ>?	MmLnV2FPT0WU
DB	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDud4pKSzVyPU[wMlk3KG6P	MmDiV2FPT0WU
HSC-4	NWfqTXpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofJTWM2OD14MT61N{BvVQ>?	NVn2WIV7W0GQR1XS
DOK	M4DFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofhTWM2OD17Mz62NkBvVQ>?	MUTTRW5ITVJ?
H9	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPZU4d1UUN3ME2xN\|cvOiCwTR?=	NEDROZNUSU6JRWK=
NCI-H292	NWrlZnBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXYS2RPUUN3ME2xOlIvPjZibl2=	M1K0SXNCVkeHUh?=
HSC-2	M{\HVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3UfpNOUUN3ME2xOlUvPTdibl2=	MX3TRW5ITVJ?
LU-65	MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIL0U2ZKSzVyPUG2Ok43OSCwTR?=	NHHFWm9USU6JRWK=
BV-173	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTF6Nj61OUBvVQ>?	NGjDRnhUSU6JRWK=
LB2241-RCC	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH[4XmVKSzVyPUG5OE46OyCwTR?=	MX;TRW5ITVJ?
KG-1	M1zudmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTJyND6zOEBvVQ>?	NUG5epNIW0GQR1XS
CHL-1	NHPTWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjibW5qUUN3ME2yNFgvPTFibl2=	NIjFZVhUSU6JRWK=
KYSE-140	NXvVWoRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLKcZFNUUN3ME2yNFkvQTZibl2=	MlXVV2FPT0WU
DU-145	M3jvO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M365ZWlEPTB;MkG5MlA1KG6P	MYLTRW5ITVJ?
EW-13	NGi4eGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrWTplKSzVyPUKyOU4yKG6P	MVvTRW5ITVJ?
KYSE-450	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nve2lEPTB;MkS3MlkzKG6P	M4GyVXNCVkeHUh?=
CAL-72	NIn0UGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\OPWlEPTB;Mk[4Mlc{KG6P	MorKV2FPT0WU
MEG-01	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2Hzc2lEPTB;Mke2Mlc3KG6P	NFq4TnZUSU6JRWK=
HCE-T	MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIH1NXhKSzVyPUK3PU44QSCwTR?=	NYr3[2N5W0GQR1XS
NCI-SNU-1	NYjaWXlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTJ6Mz6zNkBvVQ>?	NFq0d5FUSU6JRWK=
CAL-27	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PxN2lEPTB;Mki5MlA5KG6P	NILWPVdUSU6JRWK=
BALL-1	M{Doemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPXTWM2OD1{OUeuOFIhdk1?	MYLTRW5ITVJ?
SBC-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTNyNz63PUBvVQ>?	NFHqOoVUSU6JRWK=
CAL-54	NXnQVlZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PUbGlEPTB;M{GxMlI{KG6P	M3v2dXNCVkeHUh?=
TI-73	NIfVRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTOfllxUUN3ME2zNVIvPzVibl2=	MnHQV2FPT0WU
P12-ICHIKAWA	NWHRWmtkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXFWoFKSzVyPUOyPE4xPiCwTR?=	MXfTRW5ITVJ?
ACHN	NFzVZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33L[GlEPTB;M{OxMlQhdk1?	NX3xZnpoW0GQR1XS
PC-14	Ml3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M371O2lEPTB;M{OzMlQyKG6P	MYXTRW5ITVJ?
HCC1806	M33rXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\3dZVKSzVyPUOzO{42OSCwTR?=	NIfxXVdUSU6JRWK=
SK-MEL-24	NFTUdINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPK[2JoUUN3ME2zN\|cvQDdibl2=	NEXqVG5USU6JRWK=
A4-Fuk	NEfmU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLVTWM2OD1\|NUCuNFIhdk1?	NXvBdVVmW0GQR1XS
ECC10	NY\0Zo1XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTCTWM2OD1\|NUKuPVYhdk1?	NYD5OpNjW0GQR1XS
KASUMI-1	NEXBUGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTN4Nj63N{BvVQ>?	MWDTRW5ITVJ?
CAL-33	M4PiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTN5MD65JI5O	NVXUfWxHW0GQR1XS
MDA-MB-175-VII	NHfTPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTN5OD64PEBvVQ>?	M{XBXnNCVkeHUh?=
NUGC-3	M2rNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrOR\|ZKSzVyPUSwNU45OSCwTR?=	NI\iRZFUSU6JRWK=
KY821	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTRyOD61O{BvVQ>?	M4D2e3NCVkeHUh?=
CTB-1	MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{mxNGlEPTB;NEK0MlQhdk1?	MV3TRW5ITVJ?
DoTc2-4510	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTFeYFtUUN3ME20OFIvOTJibl2=	MUHTRW5ITVJ?
EFO-27	NYHlVYhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\aTWM2OD12NUSuO\|Qhdk1?	M4ThOHNCVkeHUh?=
BPH-1	NUfyTYpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTR7MT6xOkBvVQ>?	MVLTRW5ITVJ?
KYSE-270	NFe1bXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTR7OD62OUBvVQ>?	NInV[FRUSU6JRWK=
HO-1-N-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DucmlEPTB;NUC5MlI2KG6P	MmrrV2FPT0WU
SK-MEL-1	MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HEUWlEPTB;NUGwMlk6KG6P	MmTwV2FPT0WU
MOLT-13	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXLTWM2OD13MUSuPFIhdk1?	M1TJRXNCVkeHUh?=
TK10	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPjUINzUUN3ME21NVUvOTFibl2=	NYnlSo5xW0GQR1XS
HN	NHHoV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEn1ToJKSzVyPUWxO{4{QCCwTR?=	Ml7FV2FPT0WU
SCC-15	NHzBe3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2[wZmlEPTB;NUK1MlY5KG6P	NVfJd21kW0GQR1XS
NCI-H358	NH\xUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HZSWlEPTB;NUK3MlY3KG6P	NWTGSppnW0GQR1XS
KYSE-180	M1e3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jDVWlEPTB;NUOwMlYzKG6P	MnvzV2FPT0WU
NCI-H82	NEHjOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTV2MD61JI5O	MUfTRW5ITVJ?
NB7	MnXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmq1TWM2OD13NE[uN\|Ihdk1?	NVLLdZZGW0GQR1XS
DSH1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHDepVUUUN3ME21OlYvQDhibl2=	M2H3SHNCVkeHUh?=
RS4-11	NF6wdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7YTWM2OD13NkiuOVkhdk1?	MonwV2FPT0WU
CAN	NGXIb4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXRZ2sxUUN3ME21PFAvPzZibl2=	MYnTRW5ITVJ?
Ca9-22	M2\qRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTV6OD62OEBvVQ>?	MYfTRW5ITVJ?
CAL-39	Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M371PWlEPTB;NUm2MlMhdk1?	M3XMV3NCVkeHUh?=
NCI-H1623	MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrreGJKSzVyPUW5PU4{PiCwTR?=	MmPOV2FPT0WU
FADU	NGXaeHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\4TWM2OD14MESuOlkhdk1?	MVTTRW5ITVJ?
NB69	M4S0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDMN3NKSzVyPU[xOE4{PSCwTR?=	NXjBPIZkW0GQR1XS
Ramos-2G6-4C10	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTZ{MT60OkBvVQ>?	NVLydmdqW0GQR1XS
LB1047-RCC	M4XGTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTZ{NT6yPUBvVQ>?	M3zhS3NCVkeHUh?=
MV-4-11	NIHL[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPRTWM2OD14MkeuO{BvVQ>?	NETXUJdUSU6JRWK=
DBTRG-05MG	MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUL3NFBZUUN3ME22N\|IvOjhibl2=	NXPuOoo4W0GQR1XS
ME-180	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vJdmlEPTB;NkOyMlkhdk1?	MoWxV2FPT0WU
NBsusSR	MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTZ2Nj61NkBvVQ>?	NF;2eXJUSU6JRWK=
COR-L105	MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVu4eJV6UUN3ME22OlIvPTNibl2=	MkXUV2FPT0WU
ETK-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fnZ2lEPTB;Nk[yMlU6KG6P	NHzrUmZUSU6JRWK=
L-363	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPWUG1KSzVyPU[3NU46PCCwTR?=	NH\BRXBUSU6JRWK=
LU-134-A	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTdzOT6wPUBvVQ>?	NGXNNHlUSU6JRWK=
NCI-H1770	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTd{Mj60JI5O	NIjBTIJUSU6JRWK=
HAL-01	NWrYVGVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{G3XWlEPTB;N{O0MlcyKG6P	MkHLV2FPT0WU
COLO-684	M3zCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;wbGlEPTB;N{WzMlAyKG6P	Mn3xV2FPT0WU
TE-6	NYfucJZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PnTmlEPTB;N{[0MlMyKG6P	NYHJXGdnW0GQR1XS
A431	NX3FcFA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7Ge4dbUUN3ME23PFAvODRibl2=	NH\KRnlUSU6JRWK=
LU-135	Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDnW2t{UUN3ME23PFMvODNibl2=	MULTRW5ITVJ?
EC-GI-10	M{LvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTd6OD61NkBvVQ>?	NH:yUFhUSU6JRWK=
TE-12	M4\TOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTh{MT6xNUBvVQ>?	NVrIO2dTW0GQR1XS
LoVo	M1Lkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrCTWM2OD16NUmuNFYhdk1?	NX3nZVRMW0GQR1XS
23132-87	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\LbGlEPTB;OE[0MlI5KG6P	NGTofHdUSU6JRWK=
AU565	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTh4OT62JI5O	NWLMZmRMW0GQR1XS
DEL	M3K3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\pTWM2OD16N{euOlUhdk1?	Mo\qV2FPT0WU
COR-L88	NXq2ZmlUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7UfYpbUUN3ME24PFIvOjZibl2=	NFrHfmJUSU6JRWK=
NCI-H2126	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXGOmY3UUN3ME24PFIvQDNibl2=	NITNTIFUSU6JRWK=
CAPAN-1	NEXsNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkS4TWM2OD16OEOuNlkhdk1?	M1HFb3NCVkeHUh?=
BT-474	NHLQ[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXrVYZ2UUN3ME25N\|gvOTRibl2=	NWD4dJVRW0GQR1XS
BHY	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPaTWM2OD17N{WuOFghdk1?	Ml7NV2FPT0WU
HT-3	M3;HWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEiwcnpKSzVyPUm4Nk41OSCwTR?=	NELETZZUSU6JRWK=
SK-NEP-1	NYW3Oo11T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXpTWM2OD17OEmuOFQhdk1?	M2Ptd3NCVkeHUh?=
MS-1	NEnSSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zvZ2lEPTB;OUm0MlY6KG6P	MVLTRW5ITVJ?
DOHH-2	NEXzdXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\0SWlEPTB;MT6wNFAzOSEQvF2=	MV;TRW5ITVJ?
NCI-H1304	MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jQbGlEPTB;MT6wNVY1OyEQvF2=	MorvV2FPT0WU
EM-2	NX7wSZNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTFwMEOwNVYh\|ryP	NIHCbopUSU6JRWK=
MHH-PREB-1	NIT3dpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGmyVm1KSzVyPUGuNFg1PTFizszN	NVPPTW42W0GQR1XS
KU-19-19	NFzye3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjxNYdsUUN3ME2xMlA5PTRzIN88US=>	NHvMZYRUSU6JRWK=
NCI-H1648	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPwR5NKSzVyPUGuNVA3OTZizszN	M3vNUnNCVkeHUh?=
MKN1	M4L5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXf6Sox{UUN3ME2xMlIyQTh5IN88US=>	NFT6O4NUSU6JRWK=
SNU-449	MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX[3ZVl{UUN3ME2xMlIzOjB6IN88US=>	MYLTRW5ITVJ?
OAW-42	NYiyR3NDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFL5fnVKSzVyPUGuNlc5OjVizszN	MlXuV2FPT0WU
769-P	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTFwMke5NVgh\|ryP	NEnWNmVUSU6JRWK=
SW1088	M1e3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPtRXJKSzVyPUGuNlk3ODdizszN	Mmf0V2FPT0WU
GCIY	NWLjVnhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHBTWM2OD1zLkOwNVMzKM7:TR?=	MYHTRW5ITVJ?
CTV-1	MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3Kxc2lEPTB;MT6zNFgh\|ryP	M3K4WHNCVkeHUh?=
NCI-H1092	MkPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXjS4JPUUN3ME2xMlMxQDVizszN	M4\hV3NCVkeHUh?=
NKM-1	NHXvdXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkG4TWM2OD1zLkOyOVk4KM7:TR?=	Mn2yV2FPT0WU
NCI-H1650	M1TuVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrXTWM2OD1zLkOzOFgzKM7:TR?=	NULNXY0zW0GQR1XS
SW954	NHfNdpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;uPIxjUUN3ME2xMlM1ODR6IN88US=>	M3nFXHNCVkeHUh?=
SW48	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;XPIVnUUN3ME2xMlM3PjF6IN88US=>	M4TuTHNCVkeHUh?=
SK-N-DZ	Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13lNGlEPTB;MT6zOlk1PyEQvF2=	NWj5VJV{W0GQR1XS
KMOE-2	MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPHTWM2OD1zLkO5PFE2KM7:TR?=	MljxV2FPT0WU
NB5	NX;6WYF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHe0b2JKSzVyPUGuOFA5QTRizszN	NGnkU\|hUSU6JRWK=
CCRF-CEM	M4rWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPqTWM2OD1zLkSxNVEh\|ryP	MXnTRW5ITVJ?
RH-1	M2rwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4e5W2lEPTB;MT60NVE{PiEQvF2=	MXHTRW5ITVJ?
NCI-H526	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTFwNEO4NlYh\|ryP	MnXjV2FPT0WU
697	NF\CPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TwRWlEPTB;MT60OFExPCEQvF2=	NYPse5l5W0GQR1XS
J82	M1j5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4mzNmlEPTB;MT60OVc3PiEQvF2=	NVuxVG5MW0GQR1XS
BE-13	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTFwNUC2O\|Eh\|ryP	MmjqV2FPT0WU
SAS	NHnOOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvuTWM2OD1zLkWxOlIzKM7:TR?=	MULTRW5ITVJ?
SCC-25	NEWwW\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljqTWM2OD1zLkWyN\|IzKM7:TR?=	MVXTRW5ITVJ?
LAMA-84	NXTCZ3NlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\VOWlEPTB;MT61N\|gyPSEQvF2=	MVHTRW5ITVJ?
HSC-3	MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTFwNUSzPEDPxE1?	MmTYV2FPT0WU
BT-549	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXj5XHRWUUN3ME2xMlU5PzR5IN88US=>	NFXlPYNUSU6JRWK=
ML-2	NF3P[WtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHCTWM2OD1zLk[0NFI6KM7:TR?=	MmPwV2FPT0WU
BB30-HNC	M4W4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTzSpVKSzVyPUGuOlg6PzJizszN	MkPyV2FPT0WU
PANC-03-27	M{fIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\DZYpXUUN3ME2xMlcxOTN7IN88US=>	M3;KfXNCVkeHUh?=
COLO-678	M{Ppemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nMWGlEPTB;MT63N\|Q1PCEQvF2=	Mli2V2FPT0WU
NCI-H1666	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmW1TWM2OD1zLke0O\|A1KM7:TR?=	MlLhV2FPT0WU
NCI-H209	Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TaUWlEPTB;MT63O\|I3QSEQvF2=	MonWV2FPT0WU
EPLC-272H	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mny2TWM2OD1zLki1OVQ6KM7:TR?=	NUfHc\|NsW0GQR1XS
OMC-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHy4[WJKSzVyPUGuPVk5QDhizszN	MUfTRW5ITVJ?
HCC70	M2rrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFu2UZhKSzVyPUKuNFA5OTVizszN	NHrCSY9USU6JRWK=
CAL-12T	NIDVVI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PRc2lEPTB;Mj6wNVg3OSEQvF2=	NIXXV5dUSU6JRWK=
TGBC24TKB	NHu0Wm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYKyUG9bUUN3ME2yMlAzQTZzIN88US=>	M{P5SXNCVkeHUh?=
EKVX	M3zl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHxTWM2OD1{LkC0PVM6KM7:TR?=	NIDVcG5USU6JRWK=
SW1116	NFyyTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTJwME[wNFkh\|ryP	M2PGNXNCVkeHUh?=
NCI-H2009	NVPjVmJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPNS3lKSzVyPUKuNFYzOTRizszN	NF3uV4dUSU6JRWK=
RPMI-8866	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTJwMEi0PFEh\|ryP	NYTFWI9pW0GQR1XS
KARPAS-45	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUP4bJpLUUN3ME2yMlEzPDd7IN88US=>	NYK1RpZFW0GQR1XS
RXF393	NX;TPFdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDGTWM2OD1{LkGzNFM3KM7:TR?=	MX;TRW5ITVJ?
786-0	Ml6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDWbmUzUUN3ME2yMlE5PDB4IN88US=>	M4XBVXNCVkeHUh?=
SCC-4	NWj3SIxPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTJwMkG3O\|Yh\|ryP	NIrkOopUSU6JRWK=
BT-20	NG[yfYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIC0WGFKSzVyPUKuNlY4PDRizszN	NX;sbHo3W0GQR1XS
A498	NH[x[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTJwMkm0NVUh\|ryP	NHvI[XFUSU6JRWK=
IGROV-1	M3rEbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rTOmlEPTB;Mj6zNVI{PyEQvF2=	NX[xclBpW0GQR1XS
JVM-3	M2HzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3zUGdVUUN3ME2yMlM1PjR\|IN88US=>	NYf3b2NqW0GQR1XS
NCI-H2170	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTJwM{S3PFMh\|ryP	MX7TRW5ITVJ?
EW-18	M2Cxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHGxd\|NKSzVyPUKuN\|U1PzFizszN	NVfRZZUzW0GQR1XS
KU812	M3y5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHPPIFKSzVyPUKuN\|Y4PzlizszN	MVLTRW5ITVJ?
NY	NIDhboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF20eo1KSzVyPUKuN\|czPyEQvF2=	MYXTRW5ITVJ?
HTC-C3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTJwNEKyOlch\|ryP	MV3TRW5ITVJ?
CFPAC-1	NYnMXWVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\3fWJKSzVyPUKuOFM5PjRizszN	NH\WVo1USU6JRWK=
HH	M2HhNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTJwNEm4OVQh\|ryP	NUXsdldRW0GQR1XS
MKN7	NEPTV\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITVcWxKSzVyPUKuOlI4PDhizszN	NGXZNItUSU6JRWK=
TE-8	NGLhNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXIempKSzVyPUKuOlM3PTNizszN	MmjDV2FPT0WU
MC-IXC	M2TvXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFywTGpKSzVyPUKuOlQ1PTNizszN	NWLYSXRqW0GQR1XS
DMS-79	MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPWTWM2OD1{Lk[5Nlg1KM7:TR?=	M{TZTXNCVkeHUh?=
Detroit562	NIH3PFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\lTWM2OD1{Lk[5PFQ2KM7:TR?=	NWTvcGJSW0GQR1XS
HuP-T4	NGDXfYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rBSWlEPTB;Mj63NlgyQCEQvF2=	NXTKbYVlW0GQR1XS
QIMR-WIL	M{HyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3OzUWlEPTB;Mj63OVk2OiEQvF2=	M4fINnNCVkeHUh?=
BB65-RCC	NInPd2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\zToFxUUN3ME2yMlgxPzF\|IN88US=>	Mo\sV2FPT0WU
PC-3	NVi5XWJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTaTWM2OD1{LkizN\|E4KM7:TR?=	MXnTRW5ITVJ?
OVCAR-3	NFzaeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfLXnlKSzVyPUKuPFU2QTRizszN	MUXTRW5ITVJ?
KYSE-510	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TDV2lEPTB;Mj64Olc5PiEQvF2=	MUHTRW5ITVJ?
HC-1	NYH0fnBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3KeFBKSzVyPUKuPVQxOTJizszN	MYfTRW5ITVJ?
NCI-H1693	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTJwOUW4PVch\|ryP	MknhV2FPT0WU
DU-4475	M4HUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTJwOUmwOVIh\|ryP	NF7yNY1USU6JRWK=
COLO-680N	M13RNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTNwMEC0PVUh\|ryP	M1Prd3NCVkeHUh?=
MN-60	NW[0XXFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjmWVlKSzVyPUOuNFQ6PzRizszN	NHfmWZVUSU6JRWK=
BCPAP	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPydldKUUN3ME2zMlA5Ojl3IN88US=>	NEPUR5FUSU6JRWK=
647-V	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXzTWM2OD1\|LkG2NlIh\|ryP	NHH6dHFUSU6JRWK=
HT-1376	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjwfXZ4UUN3ME2zMlIxPTB4IN88US=>	Mn\0V2FPT0WU
NCI-H1793	NWn0clQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rBN2lEPTB;Mz6yNVA6QCEQvF2=	M3vqOnNCVkeHUh?=
SW1463	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnntTWM2OD1\|LkK2NVkzKM7:TR?=	MmfnV2FPT0WU
NCI-H727	NX3xfnhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTZXIp1UUN3ME2zMlM5PTh2IN88US=>	NGnlZohUSU6JRWK=
LB771-HNC	MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEm5eFNKSzVyPUOuN\|kyOjZizszN	NIjveYpUSU6JRWK=
D-542MG	NIjWR\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTNwNESyNlIh\|ryP	Mn;oV2FPT0WU
NTERA-S-cl-D1	NGHuSFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1r1SWlEPTB;Mz60OFk2PyEQvF2=	NVuyVpJDW0GQR1XS
C8166	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDufVlFUUN3ME2zMlQ3PTJzIN88US=>	MXPTRW5ITVJ?
639-V	M4j4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTNwNUe3PVIh\|ryP	NITWTHhUSU6JRWK=
TE-1	M4mwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEiyWZNKSzVyPUOuOVkyPjlizszN	MYXTRW5ITVJ?
OAW-28	NYX3OVFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTNwNUm0NlYh\|ryP	MkX4V2FPT0WU
SK-LU-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rTfGlEPTB;Mz62NFY1PSEQvF2=	NH\uW5VUSU6JRWK=
CaR-1	NXnafYxxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmL1TWM2OD1\|Lk[xNFQ5KM7:TR?=	M2\KVnNCVkeHUh?=
A2780	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnKWXJKUUN3ME2zMlY1ODh7IN88US=>	MoTuV2FPT0WU
C2BBe1	NXHIcVl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXUTWM2OD1\|Lk[0OFA4KM7:TR?=	NHn0ZphUSU6JRWK=
SK-MES-1	NWGzR2tET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTNwNkS2NVQh\|ryP	MULTRW5ITVJ?
PANC-10-05	MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFf6NoVKSzVyPUOuO\|IxPzJizszN	MWHTRW5ITVJ?
J-RT3-T3-5	NH7aOZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDLXFU5UUN3ME2zMlc2PDB4IN88US=>	NILoOItUSU6JRWK=
ES4	M{PXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjlZ4xQUUN3ME2zMlgzOjh4IN88US=>	MmPqV2FPT0WU
NCI-H28	NYfhTnA5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTuVXdqUUN3ME2zMlgzQTZzIN88US=>	NISyN\|VUSU6JRWK=
NCI-H1155	MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfIcFZKSzVyPUOuPFQyPTlizszN	NHi5RWdUSU6JRWK=
KURAMOCHI	NX;rUphiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzQTWM2OD1\|Lki2NFU3KM7:TR?=	NUnRcXdMW0GQR1XS
NCI-H69	MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF[2V4RKSzVyPUOuPVAyPzhizszN	M{XMO3NCVkeHUh?=
IST-MES1	MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnQdINzUUN3ME2zMlk1ODJ7IN88US=>	M3XVWnNCVkeHUh?=
NH-12	NWq3b2VtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrqTWM2OD1\|Lkm0NVg4KM7:TR?=	MVfTRW5ITVJ?
JVM-2	NWnW[JpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYD4NG1bUUN3ME2zMlk1PzV{IN88US=>	MX\TRW5ITVJ?
EW-16	NGHTNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PsSWlEPTB;Mz65OVU4PyEQvF2=	MknmV2FPT0WU
NCI-H441	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzJTWM2OD1\|Lkm3NFE1KM7:TR?=	MVHTRW5ITVJ?
RCC10RGB	NYXtN3l4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\wPXpKSzVyPUSuNFEzPDZizszN	MVPTRW5ITVJ?
TCCSUP	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTKN3NyUUN3ME20MlEyODVizszN	M3;QWXNCVkeHUh?=
HL-60	NIewb\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPac\|BCUUN3ME20MlEzOjRzIN88US=>	MVTTRW5ITVJ?
EW-11	NFe1fnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HZfGlEPTB;ND6xN\|I3OSEQvF2=	Ml\vV2FPT0WU
KARPAS-299	NHPiR\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPzO3VKSzVyPUSuN\|ExOTNizszN	NHfJW\|JUSU6JRWK=
SNU-C2B	NHLNbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\3TWM2OD12LkO0Olg3KM7:TR?=	NF\4NpNUSU6JRWK=
LU-139	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1z1fmlEPTB;ND6zO\|I1PyEQvF2=	NVvVemFXW0GQR1XS
HCC1937	M4XZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LiXGlEPTB;ND6zO\|k6OyEQvF2=	MnP2V2FPT0WU
GR-ST	M332dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jiSmlEPTB;ND60N\|E5KM7:TR?=	NGW5Z4NUSU6JRWK=
SK-OV-3	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF2zdoFKSzVyPUSuOFYxPDJizszN	NYLFeIc6W0GQR1XS
A172	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoOzTWM2OD12LkW1OVIyKM7:TR?=	MlftV2FPT0WU
NB10	MkHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHRTVZKSzVyPUSuOVk4QDFizszN	M{PBenNCVkeHUh?=
P30-OHK	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYH1dGlzUUN3ME20MlgyQTJ7IN88US=>	MkXmV2FPT0WU
KYSE-520	MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzCTWM2OD12Lki4NFE5KM7:TR?=	MkPWV2FPT0WU
KNS-62	MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTRwOUC4NFch\|ryP	MnHxV2FPT0WU
ES1	NHnTSGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTRwOU[wN\|Uh\|ryP	NUe1XFNNW0GQR1XS
KOSC-2	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3ruT2lEPTB;ND65PVk2QSEQvF2=	NXK0UGVXW0GQR1XS
TE-9	M1uwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rjNmlEPTB;NT6wNVUzPSEQvF2=	MnG4V2FPT0WU
NCI-H1838	NFXlW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoroTWM2OD13LkCyNFc3KM7:TR?=	MXfTRW5ITVJ?
KP-N-YN	Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV2wUYxrUUN3ME21MlEzPTlzIN88US=>	M{XtO3NCVkeHUh?=
ALL-PO	M16xR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\1TWM2OD13LkKyOVg4KM7:TR?=	NF3IPXFUSU6JRWK=
NOMO-1	NXnQN2hRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jVPWlEPTB;NT6yN\|E4PiEQvF2=	MljxV2FPT0WU
CGTH-W-1	MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHFTWM2OD13LkO4OVg1KM7:TR?=	MVXTRW5ITVJ?
ATN-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLoTWM2OD13LkSxNVg1KM7:TR?=	NX\BcFc6W0GQR1XS
AGS	MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojyTWM2OD13LkS5OlE5KM7:TR?=	NHrz[4hUSU6JRWK=
SW13	NYfUO2dwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTVwNUOyOlUh\|ryP	MWLTRW5ITVJ?
SW1990	M1fsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTVwNkKyPFUh\|ryP	NHr5eXFUSU6JRWK=
BFTC-905	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHhTWM2OD13Lk[1PFc5KM7:TR?=	M120c3NCVkeHUh?=
RMG-I	NG\icGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1[5N2lEPTB;NT62OVk1OiEQvF2=	NFy5WI1USU6JRWK=
HD-MY-Z	M1jXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzUTWM2OD13Lk[4OVgyKM7:TR?=	MljHV2FPT0WU
HCC1187	NYT1ToFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfYS5ZKSzVyPUWuO\|ExOzJizszN	M{TsOnNCVkeHUh?=
HCC2998	NETPR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnJOWJKSzVyPUWuO\|E5PzdizszN	M{D1VHNCVkeHUh?=
RT-112	NFSyOmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;rVGdKSzVyPUWuPVAzPDVizszN	MWfTRW5ITVJ?
CAKI-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTZwMEC5PFUh\|ryP	NF64UVdUSU6JRWK=
HDLM-2	MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTZwMEG0PFkh\|ryP	M{XpPHNCVkeHUh?=
TE-10	NYDJWWlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3HFPWlEPTB;Nj6wOFg{OyEQvF2=	MUXTRW5ITVJ?
KE-37	M2my[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXrycpJnUUN3ME22MlA4OjV6IN88US=>	NEXzUmpUSU6JRWK=
RCM-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTZwMEe3NVkh\|ryP	NF31PI9USU6JRWK=
Mewo	MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGW4Zm9KSzVyPU[uNVE1QDdizszN	M2WxSXNCVkeHUh?=
L-428	MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTZwMUiwN\|ch\|ryP	MUXTRW5ITVJ?
8-MG-BA	M4fvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIOyPZRKSzVyPU[uNVk{PzlizszN	NWDhS2lXW0GQR1XS
SK-MEL-28	NWKwZo84T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3r2[WlEPTB;Nj6yNFk3PyEQvF2=	MliwV2FPT0WU
VA-ES-BJ	NYj1dYdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDJSllKSzVyPU[uN\|A1PjJizszN	M1\2NnNCVkeHUh?=
CAL-120	NEXrVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2XTdmlEPTB;Nj60OVE3OiEQvF2=	M3jrXnNCVkeHUh?=
GAMG	Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXzVFR3UUN3ME22MlUxPjJizszN	NV21ZphNW0GQR1XS
MSTO-221H	NWfkZVJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jhUmlEPTB;Nj61NVE4KM7:TR?=	MYLTRW5ITVJ?
GCT	NV\lPWpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTZwNUOzPFch\|ryP	MXTTRW5ITVJ?
SH-4	M3;nZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTZwNUi4OFQh\|ryP	NITNfotUSU6JRWK=
Calu-3	NWXOfoxuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTZwNkW1Olgh\|ryP	M{O2bXNCVkeHUh?=
SK-HEP-1	NIizU5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;pe2lEPTB;Nj63NVc2OyEQvF2=	NILmPHZUSU6JRWK=
PFSK-1	MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTJelB5UUN3ME22Mlc{PDd6IN88US=>	NILZR4FUSU6JRWK=
NB12	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TqfGlEPTB;Nj63PFQxPCEQvF2=	Mn7uV2FPT0WU
A388	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTZwOEm1NkDPxE1?	NF7PfVNUSU6JRWK=
KLE	NHH1TYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTZwOU[1NVYh\|ryP	MoDhV2FPT0WU
TE-11	M{HWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUP5W2tKUUN3ME23MlA1QTZ5IN88US=>	MmPaV2FPT0WU
NCI-H2405	NGDFWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTdwMEizPVMh\|ryP	NFTGZ4VUSU6JRWK=
OVCAR-4	M4fnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TGfmlEPTB;Nz6xOVM2KM7:TR?=	MVjTRW5ITVJ?
KP-N-YS	NWfi[mRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPNTWM2OD15LkG4NVQh\|ryP	MkTaV2FPT0WU
NOS-1	M17Zdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUOzO2N5UUN3ME23MlI2QDJ6IN88US=>	NHW4NpZUSU6JRWK=
DMS-114	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPQZ\|FFUUN3ME23MlI6PjNzIN88US=>	NGXieWJUSU6JRWK=
NCI-H2030	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjTTWM2OD15LkOzOlk5KM7:TR?=	MULTRW5ITVJ?
HEL	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTdwM{e1NlEh\|ryP	NXTD[IwyW0GQR1XS
CAL-62	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1[zfmlEPTB;Nz6zPVg3PiEQvF2=	NGLHUJJUSU6JRWK=
COLO-668	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1:2NWlEPTB;Nz60N\|k3PyEQvF2=	NUPMfGF{W0GQR1XS
SKG-IIIa	M4D4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjSb41KSzVyPUeuOFU{QDFizszN	MoHNV2FPT0WU
HCC1419	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXZ[Jp1UUN3ME23MlQ3QDN\|IN88US=>	MV\TRW5ITVJ?
OS-RC-2	M37rT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTdwNEm4PVQh\|ryP	MYPTRW5ITVJ?
COLO-829	NWTSfGI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlX1TWM2OD15Lk[2OFY{KM7:TR?=	MnS2V2FPT0WU
NB13	M2[2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnCTWM2OD15LkiyOlY4KM7:TR?=	M2fsd3NCVkeHUh?=
DK-MG	MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHuTWM2OD15LkizNlAyKM7:TR?=	M2XDZXNCVkeHUh?=
SHP-77	NUXud49kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH:4bplKSzVyPUeuPFY3PTNizszN	M{H6WnNCVkeHUh?=
NCI-H661	NUXjXHRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY\YcJpDUUN3ME24MlA2QDZ5IN88US=>	M4DkWnNCVkeHUh?=
AM-38	M4qx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLUTWM2OD16LkG2Nlgh\|ryP	NUXxOGtuW0GQR1XS
VM-CUB-1	NGXQXmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\1UmlEPTB;OD6xO\|AzQSEQvF2=	NE[4XY5USU6JRWK=
KYSE-70	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvpWHVKSzVyPUiuNVk4PjFizszN	MVPTRW5ITVJ?
5637	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TtNGlEPTB;OD6zNVA2PSEQvF2=	MmrDV2FPT0WU
TGBC11TKB	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPyTWM2OD16LkS2NVY1KM7:TR?=	NXO5SGlkW0GQR1XS
EGI-1	M{S0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrKTWM2OD16Lk[wNFg5KM7:TR?=	MoWyV2FPT0WU
D-392MG	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRThwNk[yNVQh\|ryP	M17BRXNCVkeHUh?=
A673	MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHtSpVYUUN3ME24MlY4PjFzIN88US=>	NIjIZmtUSU6JRWK=
COLO-792	M2jLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\6TWM2OD16Lke0PVQ3KM7:TR?=	MojUV2FPT0WU
NCI-H1792	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXriZ\|FoUUN3ME24Mlg5QTB\|IN88US=>	MYfTRW5ITVJ?
LS-1034	NGizTXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\6dW5KSzVyPUiuPVQ3PTJizszN	MoXiV2FPT0WU
D-566MG	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHMOGRKSzVyPUmuNFE5OSEQvF2=	MUDTRW5ITVJ?
NCI-H226	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTlwMEmg{txO	NIL4NFdUSU6JRWK=
ChaGo-K-1	MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTlwMUC1O\|kh\|ryP	MW\TRW5ITVJ?
NCI-H2228	NWfMeZlwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17GW2lEPTB;OT6xNVA5OSEQvF2=	M3rlSnNCVkeHUh?=
RPMI-8226	Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH64RllKSzVyPUmuNVE{ODRizszN	NWHTUG1nW0GQR1XS
BFTC-909	M{f0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIT6[mlKSzVyPUmuNVgzQTdizszN	MXzTRW5ITVJ?
HPAF-II	NHLl[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIO1UFBKSzVyPUmuNlI2OThizszN	M3X5cHNCVkeHUh?=
Capan-2	NWOwNlFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTlwNECxNFkh\|ryP	M4TwWHNCVkeHUh?=
IA-LM	NUDGfo1jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;qWYZKSzVyPUmuOFE6PjZizszN	NGmzVoFUSU6JRWK=
KP-4	NHvDfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;RbGNbUUN3ME25MlQ5QDN6IN88US=>	MYXTRW5ITVJ?
A101D	NFzHd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{X3NGlEPTB;OT61NVcyQSEQvF2=	MXnTRW5ITVJ?
EFO-21	M2XnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTlwNUi3N\|Uh\|ryP	M3XMVHNCVkeHUh?=
C32	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfXSFBKSzVyPUmuOlM{PCEQvF2=	M2[0Z3NCVkeHUh?=
SW837	NV7TZWZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPySVhCUUN3ME25Mlg1QDJizszN	M{DjSnNCVkeHUh?=
OCI-AML2	Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHKTWM2OD17Lki2PVYh\|ryP	MnrHV2FPT0WU
NCI-H1355	NYL6PFBGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPuTHhJUUN3ME25Mlk1ODh6IN88US=>	M13TdXNCVkeHUh?=
NCI-H2342	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\tXJBKSzVyPUGwMlAyPTVizszN	NGfEOG5USU6JRWK=
A204	NX7Ndm1zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTFyLkC0OlYh\|ryP	M1;HVnNCVkeHUh?=
CAL-51	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHTVpVxUUN3ME2xNE4xQDd5IN88US=>	M1X1Z3NCVkeHUh?=
HCE-4	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\XUI51UUN3ME2xNE4yOTJ{IN88US=>	MXTTRW5ITVJ?
NCI-H810	NHfwZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTFyLkG1PVch\|ryP	M{LB[3NCVkeHUh?=
DJM-1	MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\m[mZKSzVyPUGwMlE4OzJizszN	MWXTRW5ITVJ?
SK-UT-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{P4XGlEPTB;MUCuNlU4PCEQvF2=	M{fQO3NCVkeHUh?=
U031	M{D5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnxTWM2OD1zMD6yOlg3KM7:TR?=	MVnTRW5ITVJ?
YH-13	MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTFyLkOwOVch\|ryP	MYPTRW5ITVJ?
K5	NIfoc\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7McmtKSzVyPUGwMlM{QTVizszN	NF[2PHJUSU6JRWK=
HEC-1	MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTFyLkSwPFEh\|ryP	M4fsU3NCVkeHUh?=
A2058	NYH6SHhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonhTWM2OD1zMD61OFkyKM7:TR?=	NUDlWIN[W0GQR1XS
SW962	MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fGcWlEPTB;MUCuOlIxPCEQvF2=	MmX3V2FPT0WU
VMRC-RCZ	MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvqTWM2OD1zMD62O\|Q6KM7:TR?=	MVXTRW5ITVJ?
D-336MG	M2TiUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PFbGlEPTB;MUCuO\|AxPSEQvF2=	NV;PN5p[W0GQR1XS
LXF-289	NIPPeoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnWbpNKSzVyPUGwMlc6PjdizszN	MX7TRW5ITVJ?
SW900	M1;ZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XLdmlEPTB;MUCuPFIzQCEQvF2=	NFnue2pUSU6JRWK=
K-562	MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\lT2lEPTB;MUCuPFM6PSEQvF2=	M4jXO3NCVkeHUh?=
HCC38	M17UdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTFyLkm3NVYh\|ryP	NFnL[4xUSU6JRWK=
SF-295	NEjsd21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;PUWY1UUN3ME2xNE46QTB{IN88US=>	NXTsSHA6W0GQR1XS
LB831-BLC	NGTa[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTuOXlLUUN3ME2xNU4zPTV4IN88US=>	NV;vNmNwW0GQR1XS
FTC-133	MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1Lu[mlEPTB;MUGuN\|A5OSEQvF2=	MYLTRW5ITVJ?
HCC1954	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2T4ZmlEPTB;MUGuOFM3KM7:TR?=	NH;re45USU6JRWK=
GOTO	MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{L0V2lEPTB;MUGuOVIxPiEQvF2=	M3fNO3NCVkeHUh?=
LS-411N	M2jORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nQRWlEPTB;MUGuOlExOSEQvF2=	NUfW[FU5W0GQR1XS
RPMI-7951	M4nCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7mOVUyUUN3ME2xNU43OzR6IN88US=>	NIX6S5hUSU6JRWK=
NCI-H1299	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTmTWM2OD1zMT62OlQ4KM7:TR?=	MX\TRW5ITVJ?
MLMA	M4qzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\OVJFiUUN3ME2xNU43QTl5IN88US=>	MY\TRW5ITVJ?
MMAC-SF	M{S4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnThTWM2OD1zMT63NlUzKM7:TR?=	MVzTRW5ITVJ?
UM-UC-3	NVvFe5VDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTFzLke0NlEh\|ryP	MWXTRW5ITVJ?
SCC-9	M2PIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTFzLkixOVEh\|ryP	MYjTRW5ITVJ?
HOS	NIXtcpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrNTWM2OD1zMT64Olg{KM7:TR?=	NIX3ZWFUSU6JRWK=
OE19	MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXCbG1KSzVyPUGxMlk{PjdizszN	MlriV2FPT0WU
Mo-T	Mly2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrBZXdKSzVyPUGxMlk2PDFizszN	NXLu[oRNW0GQR1XS
CAMA-1	M3XWemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoKxTWM2OD1zMj6xOlM{KM7:TR?=	M4\uSXNCVkeHUh?=
U-118-MG	MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mkf0TWM2OD1zMj6yOFQyKM7:TR?=	M2Oze3NCVkeHUh?=
KS-1	NVnvPXRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{S3d2lEPTB;MUKuNlg{OiEQvF2=	MlOyV2FPT0WU
JAR	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1mxeWlEPTB;MUKuN\|M3QSEQvF2=	MU\TRW5ITVJ?
ABC-1	NF;sVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTF{LkO0NUDPxE1?	MX\TRW5ITVJ?
Daoy	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3Ow[mlEPTB;MUKuOFU1OiEQvF2=	Mlm5V2FPT0WU
C3A	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjjU2VRUUN3ME2xNk42Pzh3IN88US=>	NUHOZ4k3W0GQR1XS
GT3TKB	Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXMR25XUUN3ME2xNk43OzJ5IN88US=>	NFSy[pdUSU6JRWK=
DMS-273	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTF{Lki2N\|Mh\|ryP	NGD4Z\|lUSU6JRWK=
G-361	NIjTSHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjmUJpSUUN3ME2xNk46OTJ7IN88US=>	M3K1enNCVkeHUh?=
RH-18	NYntT5hDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTF\|LkK5OlIh\|ryP	MXzTRW5ITVJ?
SN12C	MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2CyNWlEPTB;MUOuN\|gxQCEQvF2=	NUfnXo5rW0GQR1XS
NCI-H1993	NGe5bmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7EbW9pUUN3ME2xN{41Ojh3IN88US=>	M{S3U3NCVkeHUh?=
LOXIMVI	NELhcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzQTWM2OD1zMz62NVUyKM7:TR?=	Mn7jV2FPT0WU
SK-PN-DW	NWjV[3Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWGzOGRUUUN3ME2xN{45PDJ5IN88US=>	MkS5V2FPT0WU
KALS-1	Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTF\|Lki1NlUh\|ryP	NWHrW4V1W0GQR1XS
LAN-6	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTF2LkK1N{DPxE1?	MmnQV2FPT0WU
A549	M3[3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTF2LkS3NVIh\|ryP	NX7BWVNJW0GQR1XS
RD	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLXS3dKSzVyPUG0MlQ5OTNizszN	MXTTRW5ITVJ?
TGBC1TKB	NY\iNJppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDLUXFRUUN3ME2xOE43PjF3IN88US=>	NXLrNoJrW0GQR1XS
NCI-H630	NUnBbpFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTF2Lkm0Olch\|ryP	NGnnUFBUSU6JRWK=
MIA-PaCa-2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPTdY1qUUN3ME2xOE46PjlizszN	M1LIbXNCVkeHUh?=
NCI-H1755	M1XGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXKPI9HUUN3ME2xOE46QTV\|IN88US=>	MlfNV2FPT0WU
MOLT-4	MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTF3LkC0PVch\|ryP	MYPTRW5ITVJ?
CW-2	Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M371dmlEPTB;MUWuNVQzOSEQvF2=	MVrTRW5ITVJ?
COLO-320-HSR	NGG1SJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGn4UIRKSzVyPUG1MlU{ODdizszN	MW\TRW5ITVJ?
UMC-11	Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVr5[VFZUUN3ME2xOU44PTJ\|IN88US=>	MXvTRW5ITVJ?
MCF7	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHyTWM2OD1zNT64NVQ2KM7:TR?=	NYnocY96W0GQR1XS
NCI-H23	M{SyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7CTWM2OD1zNT64OFM5KM7:TR?=	MYDTRW5ITVJ?
HuCCT1	NWXaNnFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MW\JR\|UxRTF3Lki3OEDPxE1?	NFTlV\|ZUSU6JRWK=
MPP-89	NHrwN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTF3Lkm0NVch\|ryP	NVX6bIE5W0GQR1XS
HT55	NYPC[FJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrKc3lWUUN3ME2xOU46PDd6IN88US=>	NVjwSoxCW0GQR1XS
no-11	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGOxO\|ZKSzVyPUG1Mlk3PjNizszN	M33wV3NCVkeHUh?=
GP5d	M2WxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE[3WVVKSzVyPUG2MlIyQDdizszN	NYXNdoh7W0GQR1XS
BHT-101	NYHVSohET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTF4LkK0N\|kh\|ryP	M{nMfHNCVkeHUh?=
M059J	Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGG3WVVKSzVyPUG2MlI5PCEQvF2=	MUDTRW5ITVJ?
D-283MED	NYLNdmpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXaTWM2OD1zNj60NlA6KM7:TR?=	NVSzWJBrW0GQR1XS
BEN	Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVriS\|NsUUN3ME2xOk42OTV3IN88US=>	M4[4TnNCVkeHUh?=
LB373-MEL-D	NVzNdJQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTF4LkeyN\|Ih\|ryP	MkfLV2FPT0WU
MEL-HO	MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfVTWM2OD1zNj64PFU1KM7:TR?=	MknhV2FPT0WU
GI-ME-N	M{XZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmD3TWM2OD1zNj65NFMzKM7:TR?=	NWLvVHZ4W0GQR1XS
RKO	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTrTWM2OD1zNz6wO\|Q5KM7:TR?=	Mn[0V2FPT0WU
MZ2-MEL	NX3sd\|NVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX62ZnpzUUN3ME2xO{4yOzNizszN	MYHTRW5ITVJ?
NCI-H1573	NVfDNZgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTF5LkK4NlYh\|ryP	MnPJV2FPT0WU
NCI-H1581	M{LQN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTF5LkS0NVEh\|ryP	NIfi[FJUSU6JRWK=
NCI-H747	NF;WfGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGeyc21KSzVyPUG3MlUzQTdizszN	NFvVWWpUSU6JRWK=
SW1783	M1f5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTF5Lk[0NVUh\|ryP	MWXTRW5ITVJ?
Calu-6	NXPWPWd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTF5Lk[3PFIh\|ryP	M3LXeHNCVkeHUh?=
SF268	MmO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHmV2RKSzVyPUG3MlY6PjlizszN	MV;TRW5ITVJ?
ES8	NHzRZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVSwUnJ1UUN3ME2xO{45PTl\|IN88US=>	Ml\mV2FPT0WU
KM-H2	MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTF5Lkm0NVEh\|ryP	M{CxRXNCVkeHUh?=
D-502MG	NVyySJU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoDlTWM2OD1zNz65PFA5KM7:TR?=	MY\TRW5ITVJ?
HLE	Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTF6LkOxOFgh\|ryP	NV[1Z5h3W0GQR1XS
SW982	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzLTWM2OD1zOD60NFc2KM7:TR?=	MXXTRW5ITVJ?
MDA-MB-361	M17lVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTF6LkW1PFgh\|ryP	NHe1VZFUSU6JRWK=
NCI-H1563	MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;RdHhOUUN3ME2xPE44OTJ2IN88US=>	NFzzeXZUSU6JRWK=
MFE-280	NXTMPVZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHqPIFKSzVyPUG4MlczQTNizszN	NF\aOXpUSU6JRWK=
U251	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rBU2lEPTB;MUiuO\|M1PyEQvF2=	M1v3TXNCVkeHUh?=
KNS-42	M4i3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfzNJpKSzVyPUG4MlgxOTVizszN	MmrzV2FPT0WU
U-266	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Moi5TWM2OD1zOD64OlQ6KM7:TR?=	NFiyWGFUSU6JRWK=
OVCAR-8	MkTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnCV2F6UUN3ME2xPE46Ojd4IN88US=>	M1TU[XNCVkeHUh?=
MFH-ino	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI[zc2JKSzVyPUG4Mlk3PjlizszN	MWDTRW5ITVJ?
D-263MG	NXrmNJN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTF7LkCxO\|Ih\|ryP	NX3PR\|NUW0GQR1XS
NCI-H1437	NYrSVlJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{n6fmlEPTB;MUmuNFQ3PyEQvF2=	NFLwSFlUSU6JRWK=
NCI-H1048	M3TOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\Ve2NKSzVyPUG5MlI{OjZizszN	MlTHV2FPT0WU
NCI-H446	M2rFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPLRphKSzVyPUG5MlM2QDlizszN	NXfYV5JHW0GQR1XS
NCI-N87	NV3VbXdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;oT2lEPTB;MUmuOVk6OiEQvF2=	M4HNO3NCVkeHUh?=
WM-115	NFXzOXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTF7Lk[3O\|Qh\|ryP	M3i1UHNCVkeHUh?=
HuH-7	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTmR453UUN3ME2xPU44PDJzIN88US=>	NXLZW2dtW0GQR1XS
NCI-H650	MmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlW5TWM2OD1zOT63OVA5KM7:TR?=	M3:wSHNCVkeHUh?=
TYK-nu	NFTpVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInJ[HpKSzVyPUG5Mlg{PzhizszN	M4XqfHNCVkeHUh?=
Becker	MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHXTWM2OD1zOT64OVQ4KM7:TR?=	NEXwNlhUSU6JRWK=
BB49-HNC	NFXZR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3zHWmlEPTB;MUmuPVIh\|ryP	M4DNZ3NCVkeHUh?=
HGC-27	M1\YSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nz[2lEPTB;MkCuNVM6PCEQvF2=	NIi3c21USU6JRWK=
SiHa	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTJyLkO3NVIh\|ryP	NVj5SW5wW0GQR1XS
LB2518-MEL	MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTJyLkO3N\|kh\|ryP	NX34VG4yW0GQR1XS
TE-5	NFHkUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTJyLke0PFIh\|ryP	NYTxfWZCW0GQR1XS
IST-SL1	MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\0TWM2OD1{MD63PFc6KM7:TR?=	NYjJfVhsW0GQR1XS
A375	NX;kT\|ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\hVGk2UUN3ME2yNU4xPTZ5IN88US=>	MlPYV2FPT0WU
MC116	NIrhO41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTJzLkC3NlMh\|ryP	Mo\vV2FPT0WU
GI-1	NULCfGdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1fhUmlEPTB;MkGuNVch\|ryP	NX;XbVNRW0GQR1XS
HOP-62	Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLaTWM2OD1{MT6yO\|g1KM7:TR?=	M3XxbXNCVkeHUh?=
PA-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTJzLkK3PFch\|ryP	NHOybWRUSU6JRWK=
HT	M4XXR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\ITWM2OD1{MT60N\|MyKM7:TR?=	M2LTdHNCVkeHUh?=
HUTU-80	MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTJzLkSzN\|Yh\|ryP	NFPPWotUSU6JRWK=
NCI-H1975	NFHnZ2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DndWlEPTB;MkGuOFYyKM7:TR?=	NHvpWXBUSU6JRWK=
GAK	MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfHTYdKSzVyPUKxMlQ6QSEQvF2=	MmLGV2FPT0WU
SK-N-AS	NEH0T21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPPTWM2OD1{MT61OlE6KM7:TR?=	NUnS[VhoW0GQR1XS
OE33	M2LCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWSyT2xEUUN3ME2yNU43ODR4IN88US=>	NVPhdGVQW0GQR1XS
YKG-1	M3Hzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXjUoRkUUN3ME2yNU43PTR3IN88US=>	NGm2W2hUSU6JRWK=
CAL-85	MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTJzLkmzNFUh\|ryP	NIe1Z3NUSU6JRWK=
NCI-H2347	NIixfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3ToW2lEPTB;MkGuPVQzQCEQvF2=	M1\ST3NCVkeHUh?=
PANC-08-13	M2LlRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XV[GlEPTB;MkKuNFEyQSEQvF2=	M2jwRXNCVkeHUh?=
SK-N-FI	NFThXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjkcY1KSzVyPUKyMlMxPzRizszN	MV\TRW5ITVJ?
NEC8	M3TRTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInzdZRKSzVyPUKyMlUxPzhizszN	NXX6TpJEW0GQR1XS
AN3-CA	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3u4OWlEPTB;MkKuOlA5PCEQvF2=	NWCzeXdbW0GQR1XS
HuO9	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTJ{LkezPVYh\|ryP	MmjMV2FPT0WU
COLO-800	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvKdGVsUUN3ME2yNk44PjV\|IN88US=>	MWXTRW5ITVJ?
HT-29	M2HYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTnNoJKSzVyPUKyMlg5OjNizszN	Mnq3V2FPT0WU
OC-314	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLvWllDUUN3ME2yNk45QDR3IN88US=>	NYLi[YVLW0GQR1XS
G-401	MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LMSWlEPTB;MkOuNFQ3OiEQvF2=	M4jNOHNCVkeHUh?=
Saos-2	NELzXHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDhTWM2OD1{Mz61NVgzKM7:TR?=	MVPTRW5ITVJ?
UACC-62	NELNToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDDTWM2OD1{Mz61PFM{KM7:TR?=	MV3TRW5ITVJ?
D-247MG	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTJ\|Lke5N\|kh\|ryP	NVPzZ3lEW0GQR1XS
COLO-741	MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTJ\|Lkm1OlUh\|ryP	NUG2NFRMW0GQR1XS
ES3	M1XEZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LZUWlEPTB;MkSuNFAzOyEQvF2=	NWHUcXFrW0GQR1XS
LNCaP-Clone-FGC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTJ2LkCyNVEh\|ryP	Mm\oV2FPT0WU
SW1710	NUXLd41NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;sblJKSzVyPUK0MlE2ODZizszN	NVHwemtIW0GQR1XS
LU-99A	NV34cmp4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mly4TWM2OD1{ND6xPFQyKM7:TR?=	MYPTRW5ITVJ?
HOP-92	M2nGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTJ2LkeyOUDPxE1?	MVXTRW5ITVJ?
LS-123	MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTJ2Lkm2NVQh\|ryP	NVjHSotmW0GQR1XS
T84	MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13uUmlEPTB;MkSuPVc3PSEQvF2=	NYjONXVWW0GQR1XS
HCT-116	NGX6UYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrG[\|FKSzVyPUK1MlQyQDZizszN	M2rNeHNCVkeHUh?=
M14	NFSxWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEf5UWxKSzVyPUK1MlQ1PDdizszN	NVy1e2E6W0GQR1XS
OCUB-M	NFHHOZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTJ3LkS0OVYh\|ryP	M2q4OXNCVkeHUh?=
MKN45	M1fuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nFS2lEPTB;MkWuOlMyPSEQvF2=	MmfFV2FPT0WU
LCLC-97TM1	M1z3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\HTWM2OD1{NT63Nlg2KM7:TR?=	NFvkVJpUSU6JRWK=
RVH-421	MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnpWY1KSzVyPUK1MlgyPjFizszN	MULTRW5ITVJ?
NKS-81-FD	NGTYVolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fvPWlEPTB;MkWuPVAzOSEQvF2=	NHXJUXhUSU6JRWK=
NCI-H596	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3ZV3JKSzVyPUK2MlA1QDdizszN	MWTTRW5ITVJ?
GB-1	NIPiXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mme2TWM2OD1{Nj6xPFc6KM7:TR?=	NYfk[VAyW0GQR1XS
ZR-75-30	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTJ4LkKyPVch\|ryP	Ml\rV2FPT0WU
U-2-OS	Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDpfXBEUUN3ME2yOk4{PzV5IN88US=>	MVfTRW5ITVJ?
HuP-T3	NF\EVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jWZmlEPTB;Mk[uOlExOiEQvF2=	MUXTRW5ITVJ?
MOLT-16	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rOeGlEPTB;Mk[uOlE3PiEQvF2=	Mn;UV2FPT0WU
U-87-MG	NWPoS4hVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rN[GlEPTB;Mk[uO\|Q{QCEQvF2=	M4\aO3NCVkeHUh?=
8505C	NIfrUW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTJ4LkmxNlYh\|ryP	MXXTRW5ITVJ?
SK-MEL-3	M{PMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTJ4Lkm4Nlgh\|ryP	Mnm5V2FPT0WU
COLO-824	NWLKdpZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTJ5LkKxPVUh\|ryP	M2OyOXNCVkeHUh?=
EW-1	NFfnfIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPuV2dKSzVyPUK3MlM2PTRizszN	NV3tVo85W0GQR1XS
UACC-257	M4HWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfu[FNoUUN3ME2yO{4{QDB2IN88US=>	NV70VZhUW0GQR1XS
Hs-578-T	NHvld5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnS4TWM2OD1{Nz61Nlk6KM7:TR?=	NF33WmpUSU6JRWK=
UACC-893	NFntcWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjZTWM2OD1{Nz62OlMyKM7:TR?=	M1;ncHNCVkeHUh?=
MHH-NB-11	NX\UVpRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fHN2lEPTB;MkeuPFAxPyEQvF2=	NWDPS\|czW0GQR1XS
KYSE-410	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;5enFYUUN3ME2yPE4zPzd7IN88US=>	MVjTRW5ITVJ?
SF126	NYT3fYdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDlT2k1UUN3ME2yPE44PDN3IN88US=>	NFjGfo1USU6JRWK=
HT-144	NX\ac4ZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\DTWM2OD1{OT6zN\|YzKM7:TR?=	MmraV2FPT0WU
SW1573	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPCSG1qUUN3ME2yPU4{PTB7IN88US=>	M2X3R3NCVkeHUh?=
SW620	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTJ7LkO2OFEh\|ryP	NUezW4l4W0GQR1XS
SCH	MnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTJ7Lki4N\|Eh\|ryP	MoLhV2FPT0WU
EW-22	NEnESpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2X6fGlEPTB;M{CuNVk3QSEQvF2=	M3PLbXNCVkeHUh?=
H4	NHW5cIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHUVlZYUUN3ME2zNE41PjV2IN88US=>	Ml:0V2FPT0WU
CAS-1	M1jldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\HO2lEPTB;M{CuO\|g2QSEQvF2=	NX;LZZYyW0GQR1XS
MG-63	MlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTNyLki0O\|gh\|ryP	M1HYV3NCVkeHUh?=
MDA-MB-415	MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTNzLkG3OVMh\|ryP	M1rRcXNCVkeHUh?=
NCI-H1395	NETRPGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfEbnoxUUN3ME2zNU4zOzJ6IN88US=>	M{P0PXNCVkeHUh?=
Ca-Ski	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLhdolKSzVyPUOxMlMyPzdizszN	MlXrV2FPT0WU
BxPC-3	NF[0PGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jNVmlEPTB;M{GuN\|czQSEQvF2=	MUXTRW5ITVJ?
A3-KAW	MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnITWM2OD1\|MT60OFcyKM7:TR?=	MmKyV2FPT0WU
T-24	NHflZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrGTWM2OD1\|MT63N\|YzKM7:TR?=	NVLxR4hUW0GQR1XS
NCI-H2029	M4SxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\zXIVKSzVyPUOxMlc4PjVizszN	MlnGV2FPT0WU
YAPC	MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTN{LkC0NFch\|ryP	NFzQUJRUSU6JRWK=
SK-MEL-2	NHrvbZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzMNmlKSzVyPUOyMlA2OiEQvF2=	NGHKXVhUSU6JRWK=
LS-513	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTN{LkGxPFch\|ryP	NIHXUmlUSU6JRWK=
AsPC-1	M2XjUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTN{LkO2NFUh\|ryP	M13rc3NCVkeHUh?=
KYSE-150	M3XY[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLWTWM2OD1\|Mj6zO\|c{KM7:TR?=	NVjDR\|JUW0GQR1XS
NCI-H520	MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXPTWM2OD1\|Mj60OFgzKM7:TR?=	MmTKV2FPT0WU
JEG-3	M4DjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2qxcWlEPTB;M{OuNFk4OSEQvF2=	NWXPbo9YW0GQR1XS
GMS-10	NU\CVndMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2WzeWlEPTB;M{OuN\|AxPCEQvF2=	NF;ydpJUSU6JRWK=
HT-1080	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTN\|LkO5JO69VQ>?	NYjseW5lW0GQR1XS
NCI-H1651	M{HpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTN\|LkO5OkDPxE1?	NGLmcXdUSU6JRWK=
NCI-H2122	NWq4ZYt4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPQTWM2OD1\|Mz61OVc1KM7:TR?=	NH;sUWxUSU6JRWK=
ES5	M{DVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPl[\|FKSzVyPUOzMlczQTJizszN	NIftSGtUSU6JRWK=
8305C	NU\rTYNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWe4Nng5UUN3ME2zN{46QTN5IN88US=>	M2\xNnNCVkeHUh?=
KM12	NGDzOmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTN2LkC0O\|gh\|ryP	NHfvXGNUSU6JRWK=
HCT-15	NF\4cmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTN2LkGyO{DPxE1?	MoPvV2FPT0WU
OVCAR-5	M1jBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\aNYdUUUN3ME2zOE4zOTh{IN88US=>	NWjtNVJzW0GQR1XS
NCI-H2291	M2n4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTN2LkK0O\|Ih\|ryP	MVfTRW5ITVJ?
CP50-MEL-B	M2q1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTNTWM2OD1\|ND62OVkzKM7:TR?=	MYPTRW5ITVJ?
C-33-A	MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\0OmlEPTB;M{SuOlg2PyEQvF2=	M37rXHNCVkeHUh?=
NCI-H2452	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLoVZF4UUN3ME2zOE44QDh{IN88US=>	NELUZnFUSU6JRWK=
MDA-MB-157	MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnqXXNvUUN3ME2zOE45OTl\|IN88US=>	M4DJ[HNCVkeHUh?=
LN-405	M37rd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\qV3NKSzVyPUO1MlQ{ODhizszN	NGTicXRUSU6JRWK=
MDA-MB-231	NXrWWpJOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWqyOmFKUUN3ME2zOU42ODV2IN88US=>	NFP6TIRUSU6JRWK=
EW-24	MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTN3Lk[zN\|Uh\|ryP	NFLVfHhUSU6JRWK=
MKN28	NGTnN5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XnRmlEPTB;M{WuPFI{PiEQvF2=	M32yWXNCVkeHUh?=
KINGS-1	NGfHNopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTN3Lki0N\|Qh\|ryP	MmWyV2FPT0WU
LC-2-ad	MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\wfIFKSzVyPUO2MlY6QSEQvF2=	M2fVWXNCVkeHUh?=
IGR-1	Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;lTWM2OD1\|Nj63NFc2KM7:TR?=	NYTBOo1mW0GQR1XS
SW626	MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3LTWM2OD1\|Nz6wOFE4KM7:TR?=	MYLTRW5ITVJ?
ONS-76	NGe1SoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTN5LkGzNFkh\|ryP	NWj6W3QxW0GQR1XS
T98G	NUfmZoxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTITWM2OD1\|Nz64OlM2KM7:TR?=	MYfTRW5ITVJ?
NB14	MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnZWGpKSzVyPUO4MlQ2PDRizszN	M{XlRnNCVkeHUh?=
D-423MG	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWn1e2N1UUN3ME2zPE41QDZ7IN88US=>	MW\TRW5ITVJ?
NCI-H510A	MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvUTWM2OD1\|OD62OFUyKM7:TR?=	NYTJfm5WW0GQR1XS
NMC-G1	NGL3OJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\VTWM2OD1\|OD63NlIzKM7:TR?=	NH7BbJFUSU6JRWK=
SW948	NHXwU5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHVc3JxUUN3ME2zPE45QTR7IN88US=>	MXvTRW5ITVJ?
MFM-223	NX;JdXhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTN6Lkm0N\|Eh\|ryP	MkHBV2FPT0WU
PAN1	NVHRNI1wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XhVmlEPTB;M{iuPVkyQSEQvF2=	M1TsfHNCVkeHUh?=
MZ7-mel	M{fRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DSXGlEPTB;M{muNVE6QSEQvF2=	NFPQdWhUSU6JRWK=
COLO-679	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HBOGlEPTB;M{muPVcxQCEQvF2=	NWX5SWxIW0GQR1XS
SW872	NYHndHNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjmOGJDUUN3ME20NE4zODNzIN88US=>	NGT0S4JUSU6JRWK=
HT-1197	Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTITWM2OD12MD6yPFY6KM7:TR?=	NVLWTZk6W0GQR1XS
ES6	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfETWM2OD12MD60OVUzKM7:TR?=	NULrdJFYW0GQR1XS
SNU-387	NX[1UoMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvvOGhKSzVyPUSwMlgzOzhizszN	MorNV2FPT0WU
T47D	NXr0PFNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3qyXWlEPTB;NEGuNFE6OiEQvF2=	MULTRW5ITVJ?
G-402	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkT6TWM2OD12MT6wPFA6KM7:TR?=	M1Ho[3NCVkeHUh?=
MZ1-PC	NVTldW45T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTRzLkixJO69VQ>?	M17STXNCVkeHUh?=
SW1417	M2\RXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEGyeZVKSzVyPUSyMlMxOyEQvF2=	NXLlZm5NW0GQR1XS
RERF-LC-MS	NHfuOpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljBTWM2OD12Mj61NFg4KM7:TR?=	NFXXSGxUSU6JRWK=
SF539	NIrCNWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWG3ZVFEUUN3ME20Nk42PTJ7IN88US=>	MYPTRW5ITVJ?
ESS-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7wTWM2OD12Mz61OVU5KM7:TR?=	MoHFV2FPT0WU
RO82-W-1	Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWe2[4o2UUN3ME20N{43OTV\|IN88US=>	MXHTRW5ITVJ?
S-117	MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTR\|Lk[5OVgh\|ryP	NW\IRXJSW0GQR1XS
SW756	NVWwU2hyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLtTWM2OD12Mz64NlQzKM7:TR?=	NUS4e2IxW0GQR1XS
CP66-MEL	NY\GT\|RZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTR3LkexOFMh\|ryP	M2fENnNCVkeHUh?=
H-EMC-SS	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDXTWM2OD12NT63Olk{KM7:TR?=	MYnTRW5ITVJ?
NCI-H2052	NFPsS49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TwemlEPTB;NEWuPVAzPyEQvF2=	MYjTRW5ITVJ?
SW684	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmH6TWM2OD12Nz6wNFgyKM7:TR?=	NFLVWI9USU6JRWK=
HCC1569	NFvOR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TCOGlEPTB;NEeuNVY2QCEQvF2=	M4H2bXNCVkeHUh?=
KGN	MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\tXpBKSzVyPUS3MlM{OTFizszN	M3vR[HNCVkeHUh?=
LCLC-103H	M3rWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDFeYZnUUN3ME20O{41PDB2IN88US=>	M{mwRnNCVkeHUh?=
SW780	M2f4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPNVItKSzVyPUS3MlY{PTFizszN	MX7TRW5ITVJ?
NCI-H1703	NEW5VXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTR6LkOzOVIh\|ryP	MUTTRW5ITVJ?
HCC1395	NIfhUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrqOHhKSzVyPUS4Mlc1OzJizszN	MmnBV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-EGFR / phospho-ERK / phospho-SRC / phospho-AKT; PubMed: 22586683 Cancer Discov Effect of overexpressing CRKL on phosphorylation levels of EGFR, ERK, AKT and SRC in response to gefitinib. HCC827 cells expressing a control vector or CRKL were exposed to gefitinib at indicated concentrations for 6 h and cell lysates were collected for immunoblotting with indicated specific antibodies. Cyclin D1/ p16 / p27 / pRb; PubMed: 18559346 J Biol Chem levels of phosphorylated and total EGFR, IGF-1R, Akt, ERK1/2, and Rb and levels of cyclin D1, p27, p16, and actin following 6- or 16-h treatment of A431 cells with combinations of 1 or 3 μm gefitinib and 3 μm NVP-ADW742. Data are representative of two independent experiments. uc-caspase-9 / c-caspase-9 / uc-caspase-3 / c-caspase-3 / uc-PARP / PARP; PubMed: 23102728 Mol Oncol Apoptosis resulting from combined treatment with gefitinib and an MEK inhibitor. (A) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/wt and PC‐9/gef B4 cells. (B) Apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/wt and PC‐9/gef B4 cells. (C) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/gefE3 and PC‐9/gefE7 cells. (D) apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/gefE3 and PC‐9/gefE7 cells. PPAR-γ; PubMed: 23409107 PLoS One Fold increase relative to control was determined after normalization with β-actin as external loading control.	22586683 18559346 23102728 23409107
Immunofluorescence	EGFR / LC3; PubMed: 31196210 J Exp Clin Cancer Res H157 and H1299 cells were treated with gefitinib, or curcumin alone, or gefitinib plus curcumin at indicated concentration for 48 h and then were fixed with methanol, immunostained with anti-EGFR (green), anti-LC3 (red), and DAPI (blue), and analyzed by confocal microscopy to determine the intracellular locations of EGFR and LC3. PPAR-γ; PubMed: 23409107 PLoS One Upregulation and nuclear accumulation of PPARγ following treatment with gefitinib (24 hs). p-EGFR / β-catenin; PubMed: 23461856 FEBS J In untreated CNE2 cells, β-catenin was located in cytoplasmic membranes and cytoplasm. Treatment with EGF (50 ng/mL) resulted in increased β-catenin nuclear staining, which was reversed by either gefitinib (1 μM) or LY294002 (15 μM).	31196210 23409107 23461856
Growth inhibition assay	GI50; PubMed: 23409107 PLoS One Dose-response of bladder cancer cell lines to EGFR inhibitor (gefitinib). The GI50 value was defined as the mean concentration of drug that generates 50% of growth inhibition as compared to controls.	23409107

In vivo

Gefitinib (100 mg/kg) improves the anti-tumor effect of radiotherapy in LoVo tumor xenografts. ^[3] Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts reveals a reversible dose-dependent inhibition of tumor growth because GEO tumors resumes the growth rate of controls at the end of the treatment. ^[4]

Protocol

Cell Research:^[1]	- Collapse Cell lines: NR6, NR6M and NR6W cells Concentrations: 0-2 μM Incubation Time: 72 hours Method: Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay. (Only for Reference)
Animal Research:^[3]	- Collapse Animal Models: Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells. Formulation: 0.5% polysorbate Dosages: 100 mg/kg Administration: Once daily by oral administration (0.1 mL/10 g body weight) for 14 days (Only for Reference)

Cell Research:^[1]

- Collapse

Cell lines: NR6, NR6M and NR6W cells
Concentrations: 0-2 μM
Incubation Time: 72 hours
Method: Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay.
(Only for Reference)

Animal Research:^[3]

- Collapse

Animal Models: Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells.
Formulation: 0.5% polysorbate
Dosages: 100 mg/kg
Administration: Once daily by oral administration (0.1 mL/10 g body weight) for 14 days
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	89 mg/mL (199.14 mM)
	Ethanol	4 mg/mL (8.95 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Gefitinib (ZD1839) SDF

Molecular Weight	446.90
Formula	C₂₂H₂₄ClFN₄O₃
CAS No.	184475-35-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03292133	Recruiting	Drug: EGF816\|Drug: Gefitinib	Lung Cancer	Massachusetts General Hospital\|Novartis	October 31 2017	Phase 2
NCT03122717	Recruiting	Drug: Gefitinib\|Drug: Osimertinib	Non-Small Cell Lung Cancer	Dana-Farber Cancer Institute\|AstraZeneca	May 9 2017	Phase 1\|Phase 2
NCT02932345	Completed	--	EGFR Mutation Positive Advanced Non-small-cell Lung Cancer	AstraZeneca	October 31 2016	--
NCT02824458	Recruiting	Drug: Apatinib\|Drug: Gefitinib\|Drug: Placebo	EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors	Sun Yat-sen University	June 2016	Phase 3
NCT02804100	Unknown status	--	Carcinoma Non-Small-Cell Lung\|Bronchial Neoplasms\|Carcinoma Bronchogenic\|Lung Diseases\|Lung Neoplasms	Wenzhou Medical University	May 2016	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I try to dissolve Gefitinib (ZD1839) in 0.5% methylcellulose+0.2% Tween 80 for in vivo experiments. However, when I prepare the mixture, it forms precipitates. Exists another way to dissolve completely the compound?
Answer:
S1025 can be dissovled in both 5% DMSO+corn oil and 5% DMSO+30% PEG 300+5% Tween 80+ddH2O at 2.5 mg/ml clearly. It dissolves in DMSO not readily, please sonicate and warm it in water bath at about 45 degree, and dissolve it clearly first. Then add other solvent.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Pan EGFR Inhibitor

AZD8931 (Sapitinib) : Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.
Most Potent EGFR Inhibitor

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Related EGFR Products

Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686, AVL-301)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Choose Your Country or Region

By Signaling Pathways

By product type

Gefitinib (ZD1839)

Cited by 283 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Gefitinib (ZD1839) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products

Choose Your Country or Region

By Signaling Pathways

By product type

Gefitinib (ZD1839)

Cited by 283 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Gefitinib (ZD1839) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)